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Abstract

Attrition rates for anticancer drugs are much higher than any other therapeutic area.
Only 5% of the agents that demonstrate anticancer activity in the preclinical stages of
development demonstrate clinical efficacy in phase III trials. This high attrition rate
becomes alarming when we consider that the cost of research and development can
amount to 1 billion dollars. To exacerbate this problem, many new cancer drugs are
being discontinued, withdrawn or suspended. The reasons for this high attrition rate are
complex and may be partly attributed to suboptimal preclinical strategies such as the
use of two-dimensional (2D) cell culture systems to evaluate new agents during the
development and testing stages. Cancer cells cultured in 2D do not mimic the
complexity of the three-dimensional (3D) milieu of tumors in vivo. There is
overwhelming evidence that in vitro 3D culture systems more accurately reflect the
tumor microenvironment and present better predictive value for assessing the efficacy
of new chemotherapeutic agents. The development of 3D culture systems for
anticancer drug development remains an unmet need. Despite progress, a simple,
rapid, scalable and inexpensive 3D-tumor model that recapitulates in vivo tumorigenesis
is lacking. Herein, we report on the development and characterization of a 3D
nanofibrous scaffold produced by electrospinning a mixture of poly(lactic-co-glycolic
acid) (PLGA) and a block copolymer of polylactic acid (PLA) and mono-methoxy
polyethylene glycol (mPEG) designated as 3P. Cancer cells cultured on the 3P scaffold

xi

formed tight aggregates similar to in vivo tumors, referred to as tumoroids that
depended on the topography and net charge of the scaffold. 3P scaffolds induced tumor
cells to undergo the epithelial-to-mesenchymal transition (EMT) as demonstrated by upregulation of vimentin and loss of E-cadherin expression. 3P tumoroids showed higher
resistance to anticancer drugs than the same tumor cells grown as monolayers.
Inhibition of ERK and PI3K signal pathways prevented EMT conversion and reduced
tumoroid formation, diameter and number. Fine needle aspirates, collected from tumor
cells implanted in mice when cultured on 3P scaffolds formed tumoroids, but showed
decreased sensitivity to anticancer drugs, compared to tumoroids formed by direct
seeding. These results show that 3P scaffolds provide an excellent platform for
producing tumoroids from tumor cell lines and from biopsies and that the platform can
be used to culture patient biopsies, test for anticancer compounds and tailor a
personalized cancer treatment.

xii

Chapter One

1.1 Overview of the drug discovery program1
Advances in genomics and proteomics have rapidly increased the number of molecular
targets for therapeutic intervention to treat cancer; however the number of drugs that
advance through clinical trials in the drug discovery program is a paltry 5%. The
development of all new chemotherapeutic drugs to treat cancer follows a similar
progression. A potential drug target is identified and lead compounds are designed,
developed and screened from small molecule libraries. Preclinical testing using both in
vitro cell culture techniques and in vivo animal models, is performed to determine
pharmacokinetic and toxicological efficacy. The final step is clinical testing of the most
promising compounds in human subjects. Toxicity and lack of clinical efficacy are the
main causes of failure usually at phase 111 of clinical trials. Most pharmaceutical
companies use a set of specific high-throughput screening (HTS) assays in the
preclinical stages utilizing innovative approaches in robotics and high speed computer
technology. The common approach is to screen identified small molecule libraries using
2D monolayer cell-based assays in multiplate formats. The assays can be used to
determine empirical and mechanistic responses such as viability and cytotoxicity, signal
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A portion of this chapter have been previously published by the author in an article
entitled “A 3D Fibrous Scaffold inducing Tumoroids: A Platform for Anticancer Drug
Development”, PlosOne, October 16 2013, Vol.8, Issue 10 and have been reproduced
with permission from the publishers.
1

transduction pathways such as kinase activation or cellularresponses at the
transcriptional and translational level. Although these cell-based assays are established
in the drug discovery process their value in predicting clinical response to new agents
are limited. This lack of predictability is attributable to the fact that cells in 2D cultures do
not mimic the response of cells in the 3D environment of an organ, tissue or tumor.
Today’s strategies for drug discovery require HTS systems that can mimic the human
tissue environment to optimize preclinical and preanimal selection, thus dismissing
compounds that are ineffective and toxic while prioritizing promising candidates early in
the developmental stages. It is now recognized that 3D cell culture systems better
reflect the in vivo pathophysiological environment observed in human tissues and may
soon replace 2D cell culture systems.

1.2 The cost of drug development
It is often said that the main expense in the drug discovery program is failure. In 2011,
nearly 900 anticancer drugs were in clinical trial or under FDA review, yet only 12 drugs
were approved. It takes 10-15 years to develop a new drug from the time it was
discovered to treating patients and these numbers represents hundreds of drugs that
will not make it to market. Behind these failures are hundreds of millions of dollars spent
in research and development (R&D) and clinical trial costs. For example, from 1997 to
2011 Pfizer spent $108 million dollars and only had 14 drugs approved for market while
Novartis spent $83 million and had 21 drugs approved. R&D expenditures will top $136
billion in 2013, up from $134 billion the previous year and are on track to exceed $149
billion by 2018, according to the analysts.

2

Table 1.1 Research spending per new drug.
Company

No. of drugs
approved

R&D spending per
drug ($millions)

Total R&D spending
1997-2011
($millions)

AstraZeneca
GlaxoSmithkline
Roche
Pfizer
Johnson&Johnson
Merck & Co. Inc
NovartisAG

5
10
11
14
15
16
21

11,791
8,171
7,804
7,727
5,886
4,210
3,983

58,955
81,708
85,841
108,178
88,285
67,360
83,646

Adapted from: Inno Center for Research in Biomedical Innovation; Thompson Reuters
Fundamentals via FactSet Research Systems, 2011.

1.3 2D versus 3D cell culture systems
The culture of cells on 2D surfaces has provided important insights into tumorigenesis
and cancer biology, however most pathophysiological parameters of tumors are
minimized or lost under these conditions. Cells in 2D assume a flat and spread
morphology and can adhere freely along the horizontal plane during culture, but lack
support for extending upwards on the vertical plane [1]. Consequently, cells assume a
forced apical to basal polarity that has been shown to modulate sensitivity to apoptosis,
migration and cell signaling [2,3]. In addition, there are limited contacts with neighboring
cells confined to the flat edges that they share, in contrast to in vivo conditions where
cells closely interact with each other and the extracellular matrix at various orientations
[4]. In 2D cultures, mass transport of gases, growth factors, cytokines, hormones, or
drugs are rapidly and uniformly diffused over a short distance and equilibrate rapidly
into cells. In contrast, the three dimensional architecture of tissues, create physiological
gradients that facilitate slow diffusion across multiple layers. These gradients are
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essential for the regulation of cell signaling, homing, angiogenic sprouting, development
and the uptake of drugs [5-7]. Cell migration in 2D is confined to a restraint free plane
and encounters little or no resistance to migration from the surrounding extracellular
matrix (ECM) while in a 3D setting such as that observed during cancer metastasis,
migration is regulated by mechanical interactions with the microenvironment and cells
must often negotiate or cleave the physical matrix to extend or squeeze through.
Research have consistently demonstrated that cancer cells cultured in three
dimensional (3D) cultures exhibit behavior and expression profiles that better reflect
cancer cells in their native in vivo environment [8,9]. Observable differences between
3D and 2D are seen in cell morphology, proliferation, viability, gene and protein
expression, sensitivity to chemotherapeutic drugs, response to stimuli, and overall in
vivo relevance [10]. For example, the use of hepatoblastoma cell line (HepG2) cultured
in 2D monolayer culture is considered the gold standard in early screening of drug
candidates for hepatotoxicity. However cells in 2D culture express low levels or the
absence of drug metabolizing enzymes such as cytochrome P450s [11] in contrast with
hepatocytes in 3D collagen cultures that show responses similar to in vivo conditions.
Cells in 3D culture tend to grow slower than cells in 2D culture reflecting the Gompertz
equation, an algorithm used to quantitatively evaluate the in vivo neoplastic growth rate
[12,13]. Cells in 3D cultures show decreased sensitivity to apoptosis and display
chemotherapeutic differences in responses to drugs that may desensitize cancer cells
similar to those observed in vivo [14]. For example, MCF-7 breast cancer cells cultured
on chitosan-based scaffolds, displayed more tumor-like lactate production and drug
resistance to tamoxifen than cells cultured in 2D [15]. EMT-6 mammary cells fully
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recapitulated the cell adhesion mediated drug resistance induced in vivo but was
lacking in cultured monolayer of the same cells [16].It is evident that that the
microenvironment within which cancer cells reside contribute to the spatial and temporal
signaling domains that direct cell fate. The differences in cell behavior between 2D and
3D cultures suggest that perturbations in gene and protein expression may stem from
how cells sense and respond to microenvironmental cues that are differently expressed
in a 2D or 3D context. 3D systems have yet to be incorporated into drug development
programs because challenges exist to satisfying the criteria for HTS mainly automation,
scalability, low cost and wide applicability. However it is believed by many in the field
that it is just a matter of time. A summary of the strengths and weaknesses of 2D and
3D models are found in Table 1.2.

1.4 Types of 3D cultures in cancer research
The most common 3D models utilize matrices or scaffolds, derived from biological,
synthetic, or natural sources to form fibers, sponges, hydrogels, beads or microspheres
[17]. The biologically-derived matrices are composed of common ECM proteins such as
collagen [18], hyaluronic acid [19], gelatin [20] and chondroitin sulphate [21], that
themselves can initiate signaling cascades by acting as ligands for integrins and
receptors involved in gene expression [22]. Collagen 1, for example, targets genes
involved in motility, invasion, and migration of cancer cells by downregulating epithelial
marker expression and upregulating integrin receptor expression [23,24]. Commercially
available biological matrices such as Matrigel contain common ECM molecules found in
basement membranes such as laminin, collagen 1V, perlecan, and nidocan that activate

5

signal transduction pathways and angiogenesis [25,26]. Synthetic matrices are usually
derived from bio- degradable biocompatible polymers such as the linear aliphatic
polyesters, poly(lactic-co-glycolic acid) (PLGA) [27], poly(L-lactic acid) (PLA) [28], and
poly(e-caprolactone)(PCL) [29] and are approved by the FDA for uses in tissue
engineering and regenerative medicine applications. Examples of naturally occurring
matrices are those made from chitosan derived from crab shells [30], alginate from
seaweed [31], cellulose [32], and silk [33]. Although they lack the signaling molecules
inherent in biologically derived matrices, synthetic and natural matrices are chemically
pure and do not present the possibility of contamination from eukaryotic sources. In
addition, they impart mechanical, physical, and optical features to the scaffold and
better control over material properties. Hybrid composites containing different matrix
types are common depending on the cell and culture conditions. They may be
comprised of two or more matrices that impart mechanical or biological properties that
are lacking in the individual constructs [34,35]. A few of the most common 3D systems
are discussed below.
Fibrous scaffolds
These scaffolds mimic the filamentous ECM and possess the inherent advantages of
high surface to volume ratio, controlled porous architecture, selective adsorption of
ECM proteins and allows cells to grow at various orientations [36]. There are several
approaches to fabrication of nanofibers namely phase separation, self assembly,
template synthesis, melt blowing and electrospinning. The most widely used of these
techniques is electrospinning that can produce scaffolds consisting of random or aligned
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nanofibers. The process is simple and versatile and almost any soluble polymer can be
processed into fibers.
Hydrogels
Hydrogels are formed by the crosslinking or self-assembly of a variety of biological,
natural or synthetic materials to produce structures that contain over 90% water. A wide
and diverse range of polymer compositions and techniques have been used to fabricate
hydrogels. Depending on the type, extent of crosslinking and molecular weight between
crosslinks, the gel can be described as physical, chemical or ionotropic. Polymers and
crosslinkers can be cationic such as chitosan [29], anionic such as alginate [30],
amphipathic such as collagen or neutral such as agar; examples of synthetic polymers
are PEG and PVA. Hydrogels have limited pore size for free diffusion of water and
metabolites and exchange of nutrients and wastes, and strictly confine the overall
migration or leakage of individual cells. Thermoreversible hydrogels are used
extensively in therapeutic drug delivery because of their ability to undergo sol-gel-sol
transitions at different temperatures. To improve cell attachment and spreading for 3D
cancer cell culture applications, hydrogels are linked to adhesion ligands such as the
ubiquitous RGD (arginine-glycine-aspartate) peptides that bind to integrins on cell
surfaces. Hydrogels are increasingly used for encapsulating tumor cells within
microfluidic cell culture systems as well as for constructing nanostructures within these
devices that mimic defined topology of the native ECM.

7

Table 1.2. The Key Strengths and Weaknesses of 2D and 3D Models.
Parameters
Morphology

2D
Unnatural spreading
morphology
Limited

3D
Clustered round
morphology; lose polarity
High

Lower

Higher
Differentiate naturally as
in vivo

Gene and protein
expression

Can be made to
differentiate, rarely or
occasionally
Changes occur in gene
and protein profiles

Drug metabolism

Metabolism is artificial

Response to stimuli

Occasionally reflects
physiologic context
None or low

Value in predicting
clinical efficacy of drugs
Viability
Differentiation

In vivo relevance

Significantly more
changes occur, which
mimic in vivo
Metabolism reflects in
vivo physiological context
Mimics in vivo
High

Source: Davis et al. Three-Dimensional (3D) Scaffolds in Nano–Bio Interphase
Research, Technology and Innovation, 2011 [17].

1.5 Tumor spheroids
The most validated 3D model in cancer research is the multicellular tumor spheroid.
They have being used for a variety of experimental studies in chemotherapy and
radiotherapy and are being pursued in high-throughput screening (HTS) programs for
drug development. Spheroids appear as spherical aggregates of cells that resemble
micrometastasis and intravascular regions of tumors. Similarities are observed with
respect to histomorphological features, growth kinetics and micro-milieu [37]. Spheroids
display functional and mass transport properties attributed to differentiation patterns that
allows the appropriate cell to cell and cell to matrix interactions and appropriate ECM
assembly. Observed is the establishment of pathophysiological gradients to oxygen,
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nutrients and catabolites and the subsequent development of a central necrotic core
consisting of quiescent, hypoxic, anoxic and necrotic cell sub-populations surrounded
by a concentric arrangement of proliferating heterogeneous cells [38,39]. The metabolic
adaptation of central cells to the microenvironmental stresses created by diffusion
gradients causes the innermost cells to exit the cell cycle and enter the G0 state [40]
followed by changes in ploidy [41] extracellular pH and ECM constituents [7]. This
reflects the situation observed in vivo of proliferating tumor cells adjacent to capillaries
while innermost cells become quiescent and die by necrosis or apoptosis. The tumor
microenvironment plays a critical role in the dissemination of cancer and spheroids have
immerged as powerful tools that can model the cellular heterogeneity found in tumors.
Spheroids are amenable to coculture of different cell types such as endothelial cells,
immune cells and fibroblasts. The stroma is well known to support and respond to
tumorigenesis directly influencing the tumor process. For example it has been shown
that the human colon carcinoma cell line, HRT-18 when co-cultured with tumor
associated macrophages, stimulate tumor cell migration and inhibit tumor cell
proliferation [42]. Studies have shown that spheroids are inherently more resistant to
virtually all anticancer cytotoxic drugs than conventional monolayer cultures. For
example endometrial cancer spheroids (RL95-2 and KLE cell lines) showed more
resistance when treated with doxorubicin than cells cultured on monolayer [43].
Potential mechanisms implicate the pathophysiological gradients and the concentric
arrangement of heterogeneous cell populations within the spheroids that may affect
drug diffusion kinetics, alter expression profiles of signaling pathways, and modulate of
DNA repair mechanisms and cell cycle distribution. Several comparative transcriptomic
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studies have shown numerous genes associated with cell survival, apoptosis and drug
resistance are differentially expressed in cells grown as spheroids than in monolayer
culture [44,45].

1.6 Methods for spheroid production
A broad range of simple and complex technologies are presently being used to produce
spheroids utilizing biological, natural and synthetic materials. The most common
materials utilize biologically derived matrices such as matrigel [46], natural matrices
such as alginate and agarose [37,47] and synthetic polymers such as polyethylene
glycol (PEG) [48,49] and poly-hydroxyethyl ethacrylate (poly-HEMA). Tumor spheroids
are produced by a variety of methods that share the common feature of promoting cell–
cell attachment by resisting cell–surface connections.
Forced floating method
This method is one of the simplest methods used to generate spheroids. Modification of
the vessel surface with polyHEMA or agarose will prevent cells from attaching thereby
promoting cell–cell contacts which in turn, promote spheroid formation [50]. This method
is simple, inexpensive, reproducible and compatible with HTS. The disadvantages of
this system are that it is time consuming and labor intensive.
Hanging drop method
This method is based on the principle that surface tension at the liquid air interface
between cells, induce spheroid formation. This method is relatively simple allows for
defined sizes and has been reported to have high reproducibility producing one 3D
spheroid per drop, for numerous cell lines [51]. The disadvantages are that it is labor
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intensive, require regular media changes and changing culture medium without
compromising spheroid integrity is difficult [52].
Spinner flasks systems
These systems operate on the principle that cell suspensions kept in constant motion
either stirred or rotated, prevent cells from adhering to the container walls, and promote
cell–cell interactions and spheroid formation. Such systems are suitable for mass
production and long term culture. The drawback of using a spinner flask is that the
sheer force experienced by cells, can adversely affect the cellular physiology. Rotating
bioreactors, function by similar means as the spinner flask bioreactor but, instead of
using a stirring bar, the culture container itself is rotated. The rotating-wall vessel
developed by NASA in 1992 was designed to mimic microgravity and exert a low sheer
force on cells in culture. This low sheer force is one of the main advantages of using this
system. Other advantages are that it is simple, enables large-scale production, longterm culture and ease in changing culture medium. The limitation of using the NASA
bioreactor is that it requires specialized equipment [53].

Microfluidic cell culture platforms
Advanced spheroid methods utilize nano and micro technologies such as microfluidic
devices for the production of spheroids. Various groups have developed microfluidic
devices to culture spheroids in micro wells, micro chambers or on micro textured
surfaces. These sophisticated systems are complicated and require specially trained
personnel to fabricate and operate the devices. Many of these devices suffer from
material compatibility issues with hydrophobic drugs which may limit their applicability.
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Other problems include the inability to retrieve and characterize the spheroids and the
need to use specialized equipment that are expensive [54]. Microfluidic devices can be
adapted for HTS and can enable qualitative and quantitative analysis, continuous
perfusion and the minimal use of reagent volume.
Commercial systems
During the last few years, methods for the formation of spheroids have become
commercially available. They are mostly based on diverse gel matrix scaffolds such as
AlgiMatrix (Invitrogen), QGel and HydroMatrix (Sigma-Aldrich), or natural heteropolysaccharides that form rigid, brittle, agar-like gels (GELRITE, Sigma-Aldrich) and
NanoCulture plates from Scivax designed for high-content analysis and high through put
screening [55].

1.7 Limitations of spheroid systems
Spheroids fail to mimic the biomechanical characteristics of in vivo conditions. The
system is static compared to in vivo conditions where exchange of fluids and wastes is
a continuous process [56]. Animal-derived materials used to make spheroids risk the
potential for transmission of diseases and may present batch-to-batch variability [57].
Applications to HTS is hampered by the lack of standardized and rapid analytical
methods such as imaging and spectroscopic tools that can address typical problems
such as autofluorescence and methods to gently and rapidly recover cells for example
in hydrogels for mRNA retrieval. Non-adherent cells such as hematopoietic cell lines
are difficult to maintain in culture and may require co culture with adherent cells for
analysis. Cell manipulations on some 3D polystyrene or polycaprolactone supports
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require trypsinization that causes cell stress for [58]. To address these limitations we
constructed a novel 3D scaffold made from biodegradable biocompatible materials that
can be easily and rapidly produced. Our central hypothesis is that the scaffold can
mimic in vivo conditions and can be used to recapitulate tumorigenesis, assess
chemotherapeutic efficacy and serve as a platform for the growth of tumor biopsy.
Towards these ends we will utilize the following aims.1) Design and construct the 3D
scaffold. 2) Show that the scaffold can recapitulate in vivo tumorigenesis observed as
the induction of EMT in tumoroids.3) Demonstrate that the tumoroids can be used to
assess drug efficacy.4) Show that the scaffolds support the growth of tumor and stromal
cells from the tumor biopsy.
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Chapter Two
Design and construction of the 3D scaffold2

2.1 Introduction
Synthetic 3D substrate topography has been shown to influence cell migration,
differentiation, and gene expression similar to that observed in vivo [59,60]. During
tumor progression, the extracellular matrix modulates the phenotype of cells by
generating tensional forces within the matrix. Cells respond to these geometric cues by
restructuring their cytoskeleton which in turn translates to biochemical signals within the
cells thereby altering gene and protein expression [61]. One possible mode of this
signal transmission is mechanotransduction where physical cues are transduced via
mechanical forces to signaling pathways involved in detecting and responding to the
ECM [62-64]. This interaction is initiated at the cell-matrix interface via integrins,
communicated to focal adhesion complexes which in turn activate downstream signaling
pathways. The protein tyrosine kinase, focal adhesion kinase (FAK), responds to both
substrate rigidity and tension via the actin cytoskeleton and is an important regulator for
cells to detect and sense the topographical features in the ECM [65] [66] [67] [68,69]
[70]. In particular, the ERK/MAPK signaling cascade is activated by focal adhesion
elongation and acts as a mediator of cellular differentiation. ERK1/2 translocates to the
2

A portion of this chapter have been previously published by the author in an article
entitled “A 3D Fibrous Scaffold inducing Tumoroids: A Platform for Anticancer Drug
Development”, PlosOne, October 16 2013, Vol.8, Issue 10 and have been reproduced
with permission from the publishers.
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nucleus in cells cultured on different topographical features and affects the expression
of transcription factors and cellular differentiation [71,72]. Effects are observed on the
nucleus such as nuclear reshaping, redefinition of chromosomal territories and forceinduced alterations in nuclear pore diameter. At the transcriptional and post
transcriptional levels there may be altered physical accessibility of genes to transcription
factors and on mRNA splicing, editing or transport. At the translational level, alterations
in the activity state of proteins, conformational changes in structure, composition of
protein assemblies, and exposure of cryptic binding sites on receptors [73-75]. These
findings indicate that the architecture of the niches where cancer cells reside may be
critical for their tumorigenic behavior and therefore, drugs targeted at impairing specific
architectural features of the microenvironment should be looked at as possible novel
therapies to inhibit invasive progression. The goal of our study is to create a 3D scaffold
that would recapitulate in vivo conditions. We hypothesize that this novel 3D scaffold
would exhibit structural geometry similar to the native tumor ECM that allows the
assembly of tumors cancer cells into irregular tumor-like structures called tumoroids that
recapitulate the micrometastasis of in vivo tumors. Current 3D culture models lack the
important topographical features that define the native tumor microenvironment.
We chose a nanoscale fiber scaffold as the platform because of the ease and
reproducibility of production. Electrospinning is an excellent method for generating
fibrous scaffolds of specific composition, fiber diameter and pores from synthetic
polymers such as poly(lactic-co-glycolic acid) (PLGA) and poly(e-caprolactone). The
scaffold mimics the ECM in providing support and physical attachments. The nano- and
micro-topographic and mechanotransductive cues of electrospun polymeric scaffolds
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[76-82] have been reported to stimulate migration, differentiation and gene expression
of cancer cells [83-85]. The electrospinning conditions can be adjusted to produce
fibrous scaffolds tailored for specific cell culture needs [82,86]. Cancer cells have also
been induced to form spheroids on electrospun galactosylated fibers [87] and 3D
scaffolds [88]. However, these tumor spheroids have been poorly characterized and it is
not known whether they resemble in vivo tumors. In our preliminary study we prepared
a variety of scaffolds in order to identify optimum conditions for assembly and
construction. This required the design and construction of an in-house electrospinner
that satisfied the appropriate criteria for high energy voltage supply, a continuous flow
pump system and a contained grounded receiver. The electrospinner was easily
constructed from available materials and requires minimal maintenance and space.
The initial scaffold helped to define the parameters for electrospinning the appropriate
concentrations of polymer. We used poly(lactic-co- glycolic acid) (PLGA) because it is
an FDA approved biocompatible, biodegradable polymer. Numerous tumor cell types
grew on the PLGA scaffold as well as cocultures with stromal cells. Although this model
satisfied a simplistic approach, by providing a spatial 3D environment for cells to grow in
it did not provide the appropriate environment for the formation of in vitro tumors. We
optimized the PLGA scaffold by adding a diblock polymer made from a combination of
methoxy polyethylene glycol (mPEG) and poly(lactic acid) (PLA). Different ratios of the
polymers were used to construct the scaffolds. Most of the combinations failed except
for one which we designated 3P. The 3P scaffold mimicked the topographical and
mechanical features of the ECM and induced the self-assembly of various tumor cells
into tumoroids.To explore the effects of topography and chemistry on tumoroid
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formation, we cultured Lewis lung carcinoma (LLC-1) cells on films and scaffolds
containing various combinations of the polymers used to construct the 3P scaffold. To
determine the effects of charge, we constructed a chitosan (positively charged) 3P
scaffold and observed that tumoroid formation was inhibited or curtailed on these
constructs while the 3P scaffold formed and maintained tumoroids. Transfer of
tumoroids from the 3P scaffold to tissue culture plates resulted in complete cellular
disassociation and eventual confluency on the plates. These results underscore the
unique combination of topographical and chemical cues required to produce tumoroids
on the 3P scaffold.

2.2 Electrospinning
Electrospinning is a technique that produces scaffolds of random or aligned fibers and is
based on the principle that strong electrical forces overcome the weaker forces of
surface tension in a charged polymer liquid. At a certain threshold voltage, a charged jet
is ejected from the tip of needle. The jet moves in the direction of an external electric
field, elongates according to external and internal electrical forces, and experiences
instability. The jet segments are then deposited as a nonwoven mat of fibers on a
grounded receiver [82,86,89,90]. A typical electrospinning setup consists of a syringe
through which the liquid to be electrospun is forced, a high voltage source with positive
or negative polarity, which injects charge into the liquid, and a grounded collector
(Fig.2.1). A syringe pump is typically used to force the liquid through a needle forming a
pendant drop at the tip. An electrode from the high voltage source is directly attached to
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the metal needle. The voltage source is then turned on and charge is injected into the
polymer solution.

Polypropylene tubing
Lead cable
Enclosure box
Needle
Collector plate
High voltage supply unit
Syringe
Syringe pump

Figure 2.1. The Electrospinning equipment. The device consists of an enclosure box, a
high voltage supply unit, a syringe and a syringe pump. The enclosure box was built
from plastic and acts as an insulator to ensure safety and to minimize the effects of
environmental factors such as humidity. The syringe is attached to the pump and to the
polypropylene tubing that has a steel needle attached. The tubing and the needle are
fed through a tubing hole into the enclosure box and clamped at 20 cm from the
collector plate. The needle is connected to the power unit by attaching the positive lead
cable from the unit to a point near the needle tip using a clip.

Increasing the electric field strength causes the repulsive interactions between like
charges in the liquid and the attractive forces between the oppositely charged liquid and
collector to begin to exert tensile forces on the liquid, elongating the pendant drop at the
tip of the capillary. As the electric field strength is increased further, a point will be
reached at which the electrostatic forces balance out the surface tension of the liquid
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leading to the development of the Taylor cone. If the applied voltage is increased
beyond this point a fiber jet will be ejected from the apex of the cone and be accelerated
toward the grounded collector. The electrospinning process is governed by many
parameters. Solution parameters including viscosity and molecular weight, process
parameters such as flow rate, electric field and distance of the tip to the collector and
ambient parameters consider the temperature and humidity of the environment. These
factors play significant roles in determining the morphology and diameter of the fibers.

Figure 2.2. Schematic of the electrospinning process. The liquid polymer is placed in
the syringe that is attached to the syringe pump. The polymer is pumped through the
syringe towards the steel needle. The high voltage supply unit is switched on as soon
as a droplet of the solution is formed at the tip of the needle. The droplet becomes
charged and electrostatic repulsion counteracts the surface tension of the liquid,
causing the droplet to elongate at a critical point leading to the formation of the Taylor
cone. A fiber jet ejects from the cone, elongates by a whipping process and
accelerates towards the collector plate where the fibers are deposited.
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Fiber orientation can be controlled to produce aligned fiber assemblies that mimic those
seen, for example, in muscle and tendons and for targeted drug delivery, by introducing
various fabrication principles such as coaxial electrospinning that allows for two polymer
solutions to be electrospun simultaneously [91,92]. Electrospinning is an inexpensive
process that can be easily scaled up. It has been used extensively to produce scaffolds
for cell culture and tissue engineering applications. Considerations on the mechanical
properties of electrospun scaffolds such as topography and geometry have been shown
to influence cell behavior, gene expression, signaling, adhesion and migration [93-98].

Polymers used in electrospinning
A wide range of polymers are presently being used in electrospinning to form fibers
ranging from the micron to the nanometer scale. Numerous biological, natural and
synthetic materials are presently being used for electrospinning. Examples of natural
matrices are chitosan and silk fibroin, [99,100] and biological matrices are collagen,
fibrinogen, hyaluronic acid and gelatin [101-104]. Materials from natural and biological
sources are advantageous because of their intrinsic properties of biological recognition,
including presentation of receptor-binding ligands and susceptibility to cell-triggered
proteolytic degradation and remolding [105,106]. However, electrospinning of these
natural biopolymers is often very difficult compared to synthetic polymers because they
are difficult to process and demonstrate low mechanical strength [107]. Materials
derived from synthetic sources are commonly used and are mainly biodegradable,
biocompatible polymers such as linear aliphatic polyesters such as poly(e-caprolactone,
polystyrene, polyvinyl alcohol, poly(lactic-co-glycolic acid) and poly(lactic acid) that are
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approved by the FDA for use in tissue engineering and regenerative medicine
applications [89,108-111]. Electrospinning with copolymers offers enhancement of
polymeric materials that can improve on mechanical strength, thermal stability and
barrier properties. The use of copolymers allows for the design of new materials of
desirable properties that can enhance the characteristics of the copolymers over the
homopolymers. Biodegradable hydrophobic polymers usually possess excellent
mechanical properties but tend to lack important cell affinity properties important for cell
culture applications. Incorporation of appropriate hydrophilic copolymers can enhance,
cell affinity, morphology, pore size and other physical properties [112].

Uses of electrospun fibers
Electrospun scaffolds are presently being used in tissue engineering and biomedical
applications. For tissue engineering applications, electrospun scaffolds are generally
used as temporary templates for cell seeding, invasion, proliferation, and differentiation
prior to the regeneration of biologically functional tissues or natural extracellular matrix.
It has been shown that these scaffolds promote cell–matrix and cell–cell interactions
with the cells having a normal phenotypic shape and gene expression and electrospun
fibers mimic those found in the extracellular matrix and has demonstrated effectiveness
as a substrate for cell growth [113]. Electrospinning is the most extensively used
fabrication method for preparation of these nanometer to micron-sized fibers. Natural or
biological polymers such as collagen, alginate, silk protein, hyaluronic acid, fibrinogen,
chitosan and starch are often used for preparing scaffolds because of their
biocompatibility and signaling motifs. Electrospun scaffolds have been used to engineer
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tissues such as such as bone [114], heart [115], nerves [116] and tendons
[117].Electrospun mats have been used as drug carriers as drug delivery systems
because the large surface area allows for fast and efficient solvent evaporation, that
favors easy dispersion of the drug [118]. Depending on the polymer carrier, the release
of pharmaceutical dosage can be designed as rapid, immediate, delayed, or modified
dissolution. Drugs have been encapsulated within electrospun fibers by mixing the
drugs in the polymer solution before electrospinning [119]. A variety of drugs have been
incorporated into electrospun fibers for delivery such as the antitumor drug
hydroxycamptothecin [119], the antibiotic tetracycline [120] and the anti-inflammatory
drug Ibuprofen[121].

Synthetic polymers used to make the scaffolds
Poly(lactic-co-glycolic acid) (PLGA)
PLGA is synthesized by means of random ring-opening co-polymerization of glycolide
(GA) and lactide (LA). The structure of PLGA is shown in Fig.2.3. The rate of
degradation of the copolymer can be decreased by increasing the GA content or
increased by increasing the LA content. PLGA undergoes degradation by hydrolysis in
vivo to produce lactic acid and glycolic acid that enters the Krebs cycle and is excreted
as carbon dioxide and water. A part of the glycolic acid is also excreted in the urine.
Because these two monomers are endogenous and easily metabolized a minimal
systemic toxicity is associated with the use of PLGA for drug delivery or biomaterial
applications. The polymers are commercially available with different molecular weights
and copolymer compositions [26].
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Figure 2.3. Poly(lactic-co-glycolic acid)
x= number of units of lactide ; y= number of units of glycolide.

Poly (L-lactic acid) (PLA)
PLA is an aliphatic polyester derived from natural plants such as tapioca, sugar cane
and corn. The structure of PLA is shown in Fig.2.4. It consists of lactic acid monomers
that undergoes similar degradation by hydrolysis in vivo and attributes its hydrophobic
properties to the presence of methyl groups on the alpha carbon of the monomers. PLA
occurs naturally as the pure enantiomeric poly (L-lactic acid) with a semi- crystalline
structure. However, most types of PLA used for biological applications exist in the
racemic D and L forms and are amorphous polymers [27].

Figure 2.4. Poly (lactic acid)
n= number of lactic acid units.

PLGA and PLA are well known for their ability to undergo modifications, good
degradation behavior, scalable mechanical properties, oxygen and water vapor
permeability and high aspect ratio. Limited availability of hydrophilic functionality
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combined with surface hydrophobicity can compromise their interactions with proteins
and cells [122]. However, electrospinning counteract these hydrophobic effects, by
conferring topographical and mechanical cues such as nano to micrometer size fibers
that mimic the filamentous extracellular matrix.
Poly-ethylene glycol (PEG)
PEG is a hydrophilic biocompatible, biodegradable synthetic polymer otherwise known
as poly (oxyethylene) or poly (ethylene oxide) at high molecular weights. The structure
of PEG is shown in Fig.2.5. PEG is synthesized by anionic ring opening polymerization
of ethylene oxide initiated by nucleophilic attack of a hydroxide ion on the epoxide ring
[123]. Studies of PEG have shown that PEG typically binds 2–3 water molecules per
ethylene oxide unit. Due to both the high flexibility of the backbone chain and the
binding of water molecules, the PEG molecule acts as if it were five to 10 times as large
as a soluble protein of comparable molecular weight. These factors have been
suggested as the reason that PEG exhibits the ability to precipitate proteins and repel
cells [124,125].PEG have been combined with PLGA and PLA to form electrospun
composite scaffolds for tissue engineering and drug delivery applications[126-128].

Figure 2.5. Polyethylene glycol
n= number of poly (ethylene oxide) units.

24

Chitosan
Chitosan is a linear polysaccharide composed of randomly distributed β-(1, 4-linked Dglucosamine (deacytelated unit) and N-acetyl-D-glucosamine (acetylated unit). The
structure of chitosan is shown in Fig.2.6. It is a biocompatible, biodegradable, nontoxic,
anti-microbial and hydrating agent. Chitosan is produced commercially from chitin found
in the exoskeleton of crabs and shrimp and the cell walls of fungi. The presence of
primary aliphatic amines in the chemical structure of chitosan makes this polymer
distinct from other commonly available polysaccharides. The primary aliphatic amines of
chitosan can be protonated under acidic conditions that makes them cationic
polyelectrolytes. Chitosan with high degrees of deacetylation support the attachment of
different cell lines and this has been attributed to its tendency to form polyelectrolyte
complexes with glycosaminoglycans and the cellular attachment protein heparin [99].

Figure 2.6. Chitosan
n= no. of chitosan oligosaccharides.
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2.3 Methods
Construction of the PLGA scaffold
The PLGA scaffold was made from 3 gm of PLGA (Sigma-Aldrich) dissolved in 10 mls
of a solution of dichloromethane and chloroform (80/20 v/v). The solution was placed in
a 20 ml glass syringe attached to a polypropylene tube fitted with a 23 gauge steel
needle that was clamped at 20 cm from a copper plate covered with aluminum foil. The
syringe was attached to an automatic pump (KD Scientific) that was set a flow rate of
0.2 ml/hr. An electrode from the high voltage source (Gamma High Voltage) was directly
attached to the metal needle. The voltage was applied as soon as the polymer begins to
leave the needle. The solution was electrospun at a constant positive voltage of 20kV
[110]. The electrospun scaffolds were collected on the aluminum covered plate. The
scaffolds were gently removed then cut to approximately 7x7mm2 and placed in 96 well
plates, sterilized in isopropyl alcohol, washed three times in PBS then additionally
sterilized by exposure to high intensity UV light for one hour.
Scanning Electron microscopy (SEM)
Cells were fixed in a 50:50 (v/v) solution of 2.5% glutaraldehyde in 0.2M cacodylate
buffer (pH 7.1) for 24 hrs. The scaffolds were washed in 1% osmium tetroxide in
cacodylate buffer at 40°C for one hour. The scaffolds were washed in cacodylate buffer
then further dehydrated in an ascending series of ethanol at concentrations 10%, 35%,
50%, 70%, 95% and 100% for ten minutes. Final dehydration was done in
hexamethyldisilazane for 10 minutes. Samples were air dried, then sputter-coated with
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gold at 19.32aM for 30 seconds under argon gas [129]. Scaffolds were viewed on a Jeol
JSM 6490 scanning electron microscope.
Determination of pore size
For measurement of pore size, SEM images were taken randomly from scaffolds (n=3)
and pore sizes were measured per image (16 pores/scaffold; total=48)). To compensate
for variation in diameter, three measurements representing the shortest and longest
distances were drawn through the center of the pores and the final diameter was
calculated as the average of the value.
Cell culture
Cancer cells used in this experiment were LLC-1 , BG-1 (human ovarian cancer cells),
PC3 (human prostate cancer cells), B16 (mouse melanoma cells), MCF-7, MDA-MB231 and MCF-10A (human breast cancer cells) and WPMY-1 (human myofibroblast
stromal cells); cells were purchased from ATCC [130]. Mesenchymal stem cells (MSCs)
were derived from transgenic mice expressing green fluorescent protein (GFP) that
were purchased from Jackson Labs. Cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 1% (v/v) penicillin
and streptomycin (GIBCO). Cells were maintained in a 37°C humidified incubator with
an atmosphere of 5% carbon dioxide/95% air. Single-cell suspensions were prepared
by treatment with trypsin-EDTA (GIBCO) and resuspended in complete medium before
monolayer or tumoroid culture was set up. Cells from a single-cell suspension were
added to scaffolds in 96 well plates in a total volume of 100 µl.
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Immunofluorescence staining
Cells were washed three times with phosphate buffered saline (PBS) then fixed with 4%
paraformaldehyde in PBS for 20 minutes at room temperature, followed by
permeabilization in 1.0% Triton X-100 for 15 minutes. They were then incubated with
1% bovine serum albumin (BSA) for 30mins at room temperature then incubated with
the primary antibody overnight at 4°C. They were washed three times with PBS then
incubated with the secondary antibody for one hour at room temperature in the dark.
Primary antibody to Ki-67 nuclear antigen (mouse anti-human) (Dako) was diluted at
1:100 in 1% BSA. Secondary antibody was goat anti-mouse conjugated to Alexa 488
(Invitrogen) diluted at 1:100 in 1%BSA. Phalloidin conjugated to Alexa 555 (Invitrogen)
was diluted at 1:40 in 1% BSA. Scaffolds were washed twice with PBS before being
viewed under a microscope. For calcein acetomethoxy/ ethidium homodimer-1 (calcein
AM/EthD-1 )staining, cells were washed three times with PBS. 2ul of calcein AM (2uM)
and 2µl of EthD-1 (4 µM) were added to 1ml of PBS and gently mixed. 100 µl of calcein
AM/EthD-1 solution was added directly to cells and incubated for 20 minutes in the dark,
then washed twice with PBS before being viewed under a fluorescence microscope
(Olympus BX51) or a confocal microscope (Leica TCS).
CellTracker staining
For coculture experiments cells grown to confluency were washed with PBS twice and
single-cell suspensions were prepared by treatment with trypsin-EDTA; 1x104 cells were
resuspended in I ml of pre warmed serum free DMEM media. This was added to 1.0 ml
of pre warmed Celltracker Green (0.3125µM) or Celltracker Orange (2.5µM) in serum
free media and incubated in a 37°C humidified incubator with an atmosphere of 5%
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carbon dioxide/95% air for 45 mins. The solution was gently spun at 1200 rpm for 3
minutes then the supernatant was removed and the cells were incubated in 1 ml serum
free media for 30 mins at 370C .The media was removed and replaced with 1ml DMEM
media containing 5% FBS and 1 %( v/v) penicillin and streptomycin. Equal
concentrations of cancer cells and stromal cells (5x103) were added to a culture
chamber and maintained in a 37°C humidified incubator with an atmosphere of 5%
carbon dioxide/ 95% air for 24hrs. Cells were washed three times then fixed with 4%
paraformaldehyde for live viewing using a wet lens under a confocal microscope [131].
Synthesis of methoxy PEG-PLA copolymer
Methoxy PEG-PLA block copolymer was prepared by ring-opening polymerization.
Briefly, 3, 6-dimethyl-1, 4-dioxane-2, 5-dione (LA) was dried in a vacuum oven at 400C
overnight. 1.0 gm of mono-methoxy poly (ethylene glycol) (mPEG) was placed in a
flame dried 100ml three-necked round-bottom flask and stirred at 80°C under vacuum
overnight. Various amounts of dried LA polymer (1gm, 2gm, 4gm and 10gm) and 0.5 µl
of 0.2 wt% stannous octoate (Sn (Oct) 2) were added to the flask under the protection
of argon gas. The mixture was dissolved in 20 ml anhydrous toluene and heated at
140°C under argon gas for 5 hours. Solid products of the diblock copolymers were
obtained by adding the sample solutions to 30 mls ice cold diethyl ether. The products
were dissolved in 2 mls dichloromethane and precipitated in 30 mls cold diethyl ether
twice, for purification. The final copolymer was dried in a vacuum oven at 50°C for 48
hours [126].
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Figure 2.7. Schematic of the synthesis of the mPEG-PLA copolymer
m= number of poly(ethylene oxide) units; n= number of lactide units.

Fourier Transformed Infrared spectroscopy (FTIR)
FTIR was used to determine if the mPEG/PLA copolymer was successfully synthesize
and to determine the structure of the polymer. 2 gm of the mPEG-PLA polymers were
dissolved in I ml chloroform and 0.5 mls were added to the surface of the polyethylene
IR card. The chloroform was allowed to evaporate in a vacuum oven (500C) overnight
before putting the card into a Thermo Scientific IR200 spectrometer for analysis. Fourier
transform infrared spectra represented an average of 64 scans in the mid-IR
wavenumber range 400–4000 cm1 with a spectral resolution of 4 cm1. Background
scans were obtained from a blank IR card [132].
Proton Nuclear Magnetic Resonance Spectroscopy (1H NMR)
1

H NMR was used to determine the molecular weight and structure of the mPEG/PLA

copolymer. 0.5gm of the mPEG-PLA polymer was dissolved in I ml deuterated
chloroform (CDCl3) in a 3ml tube then transferred to a 5mm NMR tube. All spectra were
measured by using a Bruker AVANCE DRX 500 instrument operating at 500.13 MHz.
The Bruker XWIN-NMR software version 3.5pl5 running on a standard PC was used for
acquisition of all spectra.
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Construction of the scaffolds
For construction, 3 gm of mPEG-PLA (mPEG: PLA 1:1, 1:2, 1:4 and 1:10) were mixed
with 1.2 gm of PLGA and dissolved in 5mls of a solution of dichloromethane and
chloroform (80/20 v/v). The solution was placed in a 20 ml glass syringe attached to a
polypropylene tube fitted with a 23 gauge steel needle that was clamped at 20 cm from
a copper plate covered with aluminum foil. The syringe was attached to an automatic
pump that was set a flow rate of 0.2 ml/hr. An electrode from the high voltage source
was directly attached to the metal needle. The voltage was applied as soon as the
polymer begins to leave the tip of the needle [110]. The electrospun scaffolds were
collected on the aluminum covered plate. The scaffolds were gently removed from the
plate then cut to approximately 7x7mm2 and placed in 96 well plates, sterilized in
isopropyl alcohol, washed three times in PBS then additionally sterilized by exposure to
high intensity UV light for one hour.
Construction of chitosan composite and PLGA/PEG scaffolds
The chitosan coated scaffolds were constructed by immersion of scaffolds in 1wt%
chitosan (deacetylation>95%) in 1% acetic acid solution for four days. The chitosan
solution was removed and the scaffolds were washed with PBS three times then
sterilized under UV light for one hour prior to cell culture. The PLGA/PEG scaffolds were
constructed by immersion of scaffolds in 1% wt% PEG in dH2O for 3 days. The solution
was removed washed with PBS three times then sterilized under UV light for one hour
prior to cell culture.
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Construction of Films
For the PLGA /mPEG-PLA film 3 gm of mPEG-PLA was mixed with 1.2 gm of PLGA
and dissolved in 5mls of a solution of dichloromethane and chloroform (80/20 v/v). 100µl
of the solution was delivered onto 22x30 mm glass coverslips and the solvent was
allowed to evaporate for 24hours then sterilized under UV light for one hour prior to cell
culture. For the mPEG-PLA film 60 mg of the polymer was dissolved in 1ml of a solution
of dichloromethane and chloroform (80/20 v/v) and 100µl of the solutions were delivered
onto 22x30 mm glass coverslips and the solvent was allowed to evaporate for 24 hours
then sterilized under UV light for one hour prior to cell culture.
Migration assay
For the migration assay, day 10 tumoroids were transferred to a tissue culture plate
containing complete DMEM medium and the migration was monitored from day 2 to day
4 by direct viewing under a light microscope or stained with calcein AM /EthD-1 stain
and viewed under a fluorescent microscope. Tumoroids were also transferred to new 3P
scaffold and similarly stained and observed.
Tumoroid diameter and number estimation
For measurement of tumoroid diameter, at least 4 scaffolds/time points and 5
tumoroids/ scaffold were examined. Five fluorescent images were taken randomly per
scaffold with at least one spheroid captured per image. To compensate for variation in
radii, two diameters representing the shortest and longest diameters were drawn
through the center of the tumoroid and the final diameter was calculated as the average
of both values using Image J software. Tumoroid numbers were counted from images
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taken systematically across each scaffold. Aggregates of size ≥50 µm were counted as
tumoroids. For longer term culture greater than eight days, scaffolds were transferred to
larger wells to accommodate demanding nutrient requirements. Larger tumoroids can
be easily detached from the scaffold using gentle pipetting and transferred to new
scaffolds. Tumoroids and monolayer cells were stained with calcein AM/EthD-1 stain.
The scaffolds were placed on glass slides, covered with glass coverslips then viewed
under a microscope.
Statistical analysis
Quantitative data were expressed as mean +/- standard deviation. Student’s t-test was
used to analyze the statistical significance of the data between groups. Values with p<
0.05 were considered statistically significant. All experiments were performed in
triplicate.

2.4 Results
Growth and proliferation of cells on the PLGA scaffold
The PLGA scaffolds provided structural support and shape to cells, allowed cell
attachment, provided good spatial interconnectivity, a high surface-to-volume ratio and
good porosity for fluid transport. Confocal image (Fig.2.8A) and SEM image (Fig.2.8B)
of the PLGA scaffold showed randomly aligned fibers that combine to form a highly
porous mesh. A 3D confocal image of PC3 prostate cancer cells cultured on the scaffold
showed that cells grew in all orientations (Fig.2.8C). The parameters that affected the
pore size, diameter and thickness of the scaffold included voltage, distance from needle
tip to the surface of the collecting sheet and concentration of the polymers in the

33

solvent. The diameter of the fibers and pore size were calculated from the SEM images
and ranged from 0.61 to 4.95 µm with pores of mainly subcellular sizes (<10 µm).

A

B

C

Figure 2.8. PLGA scaffolds. (A) Confocal image of a PLGA scaffold showing a random
mat of fibers forming a highly porous mesh. The scaffold was imaged green using the
green filter of the confocal microscope and indicates the auto- fluorescence of the
scaffold. (B) SEM images of PLGA scaffolds were used to determine the diameter of the
fibers (0.61 to 4.95 µm) and pore size (<10 µm). (C) Confocal image showing the 3D
orientation of PC3 prostate cancer cells growing in all directions and were not limited to
surface areas alone. PC3 cells were cultured for 48 hrs. The scaffold fibers appear blue
using the blue filter of the confocal microscope. Actin filaments (red) were stained with
phalloidin conjugated to Alexa 555.

Various cell types grew and proliferated on the scaffold. This included mesenchymal
stem cells (MSCs) (Fig.2.9), PC3 prostate cancer cells and 3T3 fibroblast cells
(Fig.2.10). Recognizing the role of the tumor stroma in cancer growth and
differentiation, we wanted to determine if the scaffold could accommodate the growth of
cocultured cells. We cocultured PC3 cells with WPMY-1 prostrate stromal cells on the
PLGA scaffold and on monolayer. Results from images of cells stained with Celltracker
dyes that allowed for live cell imaging and immunostaining for the nuclear antigen Ki-67
present in proliferating cells, showed that cocultured cells grew and proliferated on the
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scaffold (Fig.2.11). Ki-67 is a cell marker for proliferating cells, and is strictly observed in
cells undergoing active phases of the cell cycle, but is absent in resting cells. The PLGA
scaffold provided the appropriate 3D environment for cells to grow and supplied the
template for optimizing the next generation of scaffolds.

A

B

C

Figure 2.9. Growth of mesenchymal stem cells on PLGA scaffolds. Bone marrow
derived mesenchymal stem cells were obtained from transgenic GFP mice. (A) SEM of
monolayer of cells that were cultured for 48hrs. (B) SEM of MSCs on scaffold that were
cultured for 48 hrs. (C) Confocal image of MSCs (green) on scaffold that were cultured
for 48 hrs. Actin filaments (red) were stained with phalloidin conjugated to Alexa 555.
The scaffold appears light green using the green filter on the confocal microscope.

Characterization of the mPEG-PLA polymer
To optimize, we chemically modified the PLGA scaffold with the addition of mPEG-PLA
polymer. The synthesis of mPEG/PLA was confirmed by FTIR and 1H NMR. In the FTIR
spectra the major peaks assigned to the copolymer mPEG-PLA were 2850 – 2950 cm-1
(C-H stretching of CH3), 1760 cm-1 (ester C=O stretching) and 1087- 1184 cm-1 (OCH2 stretching) (Fig.2.12). The molecular structure of the mPEG-PLA copolymer was
characterized by 1H NMR (Fig.2.13). The molecular weight of the PLA block of the
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mPEG-PLA copolymer was determined to be 23.1kDa using the intensity of the terminal
methoxy proton signal at 3.39ppm as the internal standard.

PLGA scaffold

3T3 cells

PC3 cells

Monolayer

Figure 2.10. Growth of PC3 and NIH 3T3 cells on PLGA scaffolds. PC3 cells were
cultured for 48hrs on monolayer or on PLGA scaffold. 3T3 fibroblast cells were cultured
for 48hrs on monolayer or on the PLGA scaffold. SEM of both cell types shows the
morphological differences of cells on 2D monolayer versus 3D scaffold. Cells on the
monolayer appear to have a spread morphology compared to those on the scaffold.
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Fig 10 Coculture of PC3 and WPMY-1 on monolayer and on

E
D
scaffold. Cells were stained with Celltracker
membrane dye.

Fig 3:11 Co-culture of PC3 tumor cells (green) and WPMY-1 cells (red) on
monolayer and on scaffold. Cells were stained with Celltracker membrane
dyes.

Figure 2.11. Coculture of PC3 and WPMY-1 stromal cells on PLGA scaffolds. (A)
2D monolayer coculture of PC3 cells (green) and WPMY-1 stromal cells (red). Cells
were stained with Celltracker dyes and cocultured for 24 hrs before viewing using a wet
lens on the confocal microscope. (B) Coculture of PC3 cells and WPMY-1 stromal cells
on PLGA scaffold. (C) Enhanced confocal image of PC3 cells interacting with WPMY-1
stromal cells on the PLGA scaffold. (D) Proliferating PC3 and WPMY-1 stromal cells
(green) on monolayer. (E) Proliferating PC3 and WPMY-1 stromal cells (green) on
PLGA scaffolds. Cells were immunostained for the nuclear antigen Ki-67 (green) which
is expressed in proliferating cells, and counterstained with phalloidin conjugated to
Alexa 555 (red). The scaffold is imaged blue (B, E) using the blue filter of the confocal
microscope.

The scaffolds
Scaffolds were constructed from a mixture of various mPEG-PLA copolymers and
PLGA. The scaffolds were designated multilayered nanofiber (MN) scaffolds. Table 2.1
highlights the characteristics of the MN scaffolds. The MN 1:1 and MN1:2 polymers
were not amenable to electrospinning while the MN1:4 and MN 1:10 readily
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electrospun. The MN 1:10 polymer either did not form tumoroids or formed loose
aggregates that did not resemble tumoroids while the MN1:4 polymer formed tumoroids
with LLC-1 and PC3 cells (Fig. 2.14). Henceforth the MN1: 4 scaffold is referred to as
the 3P scaffold.

mPEG-OH
mPEG-PLA-OH

Figure 2.12. FTIR of mPEG-PLA polymer. FTIR shows strong absorption at 1760
cm-1 assigned to the –C=O stretch of PLA. The stretch of the C-O-C band of the
mPEG and PLA is shown at 1087 and 1184 cm-1, respectively. The peaks at 2850
and 2950 represent –CH2 stretching of the mPEG, confirming that the mPEG-PLA
polymer was successfully synthesized.

Growth of tumoroids on the 3P scaffold
SEM of the 3P scaffold showed the diameter of the fibers ranged from 0.69 to 4.18 µm
with pores of mainly sub cellular sizes (<10 µm) (Fig. 2.15A). There were no differences
observed in the pore size or diameter of the 3P scaffolds versus the PLGA scaffolds.
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The SEM images of LLC-1 (Fig.2.15B) and MCF-7 (Fig.2.15C-D) tumoroids showed
typical morphology with a smooth surface, tight cell junctions and indistinguishable
cellular boundaries. SEM image of MCF-7 cells show intertwining of the fibers into and
around the tumoroids that allows for anchoring and stabilization (Fig.2.15C). We
compared the growth of LLC-1 cells on the 3P scaffold with cells cultured on monolayer
and on PLGA and observed that cells did not form tumoroids on monolayer or on PLGA
scaffolds, but cells cultured on the 3P scaffold formed tumoroids on day 3 that
increased in size on day 5 (Fig.2.16). Images (100x) were taken systematically across
each scaffold and a composite of these images show tumoroid distribution on day 3
(Fig.2.17).

(B
)

(C
)

(A
)
(D
)
Figure 2.13. 1H NMR of mPEG-PLA polymer. The molecular structure of the mPEGPLA polymer is shown. Peak ‘A’ is assigned to the methyl group and (-CH3) and ‘C’ to
the methylene protons (-CH-) in the PLA units. The peak at ‘B’ is attributed to the
methylene protons of PEG oxyethylene units. The small peak at ‘D’ is attributed to the
methylene protons of -O-CH2-CH2- in the PEG end block that linked to PLA.
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Tumoroid size and numbers
The average diameter of LLC-1 tumoroids grown on a 3P scaffold at initial density of
5x103 per ml for days 2, 3, 4, 5, and 8 were 93 µm, 200 µm, 211 µm, 279 µm, and 325
µm, respectively. The average tumoroid number/ scaffold were 20, 55, 58, 59 and 66
respectively (Fig.2.18). The minimum size of 50 µm was used as the cutoff point
because at this size tumoroids have begun to develop 3D cell-cell interactions over cellmatrix interactions.

MN1:4

MN1:10

LLC -1

PC3

Figure 2.14. Growth of cells on the MN scaffolds. LLC-1 cells (5x103) were cultured
for three days on the MN1:4 and MN1:10 scaffolds. Tumoroids formed on the MN1:4
scaffold but not on the MN1:10 scaffold. Scale bar=100µm. PC3 cells (7x103) formed
tumoroids at day5 on the MN1:4 scaffold while cells on the MN1:10 scaffold formed
loose aggregates that did not resemble tumoroids. Cells were stained with calcein
AM/EthD-1 that stains live cells green and dead cells red. Scale bar=50 µm.
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Table 2.1. Characteristics of the Scaffolds.
Name

Electrospinning
potential

Cell
growth

Tumoroid
formation

Fiber
diameter

Pore
size

PLGA

Yes

Yes

No

0.614.95µm

<10µm

MN1:1

No

NA

NA

NA

NA

MN1:2

No

NA

NA

NA

NA

MN1:4

Yes

Yes

Yes

0.694.18µm

<10µm

MN1:10

Yes

Yes

Variable

Not
tested

Not
tested

NA= Not applicable
The MN1:4 scaffold was renamed the 3P scaffold.
Long term tumoroid culture
For long term culture, scaffolds were transferred to larger wells to accommodate
demanding nutrient requirements. Larger tumoroids were detached from the scaffold
using gentle pipetting and transferred to new scaffolds. We followed tumoroid growth on
the scaffold on days 10, 14 18 and 20 and observed that tumoroid diameter increased
over time. Typically, tumoroids exhibit a spherical proliferative geometry and beyond the
diffusion capacity of oxygen and fresh growth medium the innermost cells become
quiescent and die resulting in the development of a necrotic core. This was observed in
day 20 tumoroids that had attained diameters >500 µm (Fig.2.19).
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A

B

C

D

Figure 2.15. SEM of tumoroids on the 3P scaffold. (A) SEM of 3P scaffold. Fiber
distribution in the 3P scaffold shows a random mat of fibers interspersed with pores.
SEM was used to determine fiber diameter as 0.69-4.18µm and pore size <10 µm.
(B) LLC-1 tumoroid growing on the 3P scaffold that was cultured for 3 days. (C-D)
SEM images of an MCF-7 tumoroid cultured on the scaffold for 7 days. (C) This
image shows the intertwining of the fibers through the tumoroid anchoring and
stabilizing it to the scaffold. (D) A representative image of the entire tumoroid.
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PLGA

3P

Day 5

Day 3

Day 1

Monolayer

Figure 2.16. Growth of tumoroids on scaffolds: LLC-1 lung cancer cells (5x103)
were cultured on monolayer, PLGA and 3P scaffolds from day 1 to day 5. Cells
cultured in monolayer and PLGA scaffold grew but did not form tumoroids for all
days observed. Cells cultured on 3P scaffold, formed tumoroids on day 3 that
increased in size on day 5. Cells were stained with calcein AM/EthD-1 that stained
live cells green and dead cells red. Scale bar = 50µm.

43

500

80

Tumoroid Diameter (mm)

Number of Tumoroids

Figure 2.17. Composite image of tumoroids on a 3P scaffold: A
representative composite image of LLC-1 tumoroids on a 3P scaffold (day 3) viewed
under fluorescence microscope (100x). This image represents the distribution of
tumoroids on a single scaffold. Tumoroids were stained with calcein AM/EthD-1
stain. Scale bar =500µm.
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Figure 2.18. Tumoroid numbers and sizes. The average tumoroid number per
scaffold from day 2 to day 8 went from 20 to 67. Tumoroid numbers were counted
from images taken systematically across each scaffold (n=4 scaffolds/time point).
The average size of tumoroids for day 2 to day 8 ranged from 93 to 325 µm,
respectively. The data is presented as mean +/-SD; n= 4 scaffolds/time points and 5
tumoroids/ scaffold.
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Day10

Day14

Day18

Day20

Figure 2.19. Day10 to day 20 tumoroids. Representative images of day 10 to day 18
tumoroids taken with a light microscope. Tumoroids were stained with calcein AM/EthD1 that stained live cells green and dead cells red. The day 20 tumoroid was taken with
a confocal microscope and Z stack imaging shows the central area of necrosis that is
typical of tumoroids that have diameters greater than 500 µm. Scale bar =500µm.

Parameters for tumoroid formation
The parameters essential for tumoroid formation depended on concentration of cells,
the type of cells and the time from initial seeding of the cells. Density studies of LLC-1
cells cultured at concentrations 3x103-1x104 at day1- day 5 showed that cells formed
tumoroids at different time points and concentrations and that the higher the
concentrations of cells, the faster the tumoroids were formed with subsequent increase
in tumoroid diameter over time. Growth kinetics showing the relationship between the
growth rate of the tumoroids and the concentration of cells is seen in Fig.2.20. All cell
types cultured on the scaffold formed tumoroids. This included B-16 melanoma,BG-1
ovarian cancer cells, MCF-7, MDA-MB-231 and MCF-10A breast cancer cells(Fig.
2.21). Irrespective of tumor types, these cell lines grew tumoroids at different times. For
breast cancer cell lines, the highly invasive MDA-MB-231 grew tumoids faster than the
less invasive MCF-7 and MCF-10A cells. However, MCF-7 and MCF-10A cells grew
larger tumoroids than MDA-MB-231 cells.
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1x10
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Day 5
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Figure 2.20. Seeding density and tumoroid formation. LLC-1 cells were cultured at
concentrations 3x103 to 1x104/ scaffold from day 1 to day 7. Cells were stained with
calcein AM/EthD-1 to detect live (green) and dead (red) cells. It was observed that the
higher the concentrations of cells, the faster the tumoroids were formed with
subsequent increase in tumoroid diameter over time. Scale bar =50µm.
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Effects of topography on tumoroid formation
Physico-chemical cues may be responsible for tumoroid formation on the 3P scaffold.
Deconstructing the mechanical and chemical components of the scaffold may aid in
understanding these mechanisms. We cultured cells on an mPEG-PLA scaffold and
compared growth with cells on PLGA scaffolds and on monolayer. Cells grew on
PLGA/PEG scaffolds, PLGA scaffolds and on monolayer, but did not form tumoroids
(Fig.2.22). To explore the effects of topography on tumoroid formation, we cultured LLC1 cells on 3P films made from polymers used to construct the 3P scaffold and on
mPEG-PLA films. Cells on the 3P film formed tumoroids that easily dissociated when
the substrate separated from the slide on day 5. Cells on the mPEG-PLA films grew into
large disorganized aggregates that lacked the defined shape and structure of a
tumoroid and also dissociated by day 5 (Fig.2.23). This underscores the contribution of
topography and chemistry in the maintenance of tumoroid integrity.
Effects of charge on tumoroid formation
To elucidate the effects of charge on tumoroid formation we constructed a composite
3P/Chitosan scaffold. We used chitosan because it is a naturally occurring
polysaccharide with a net positive charge at physiological pH which would increase the
hydrophilic properties of the scaffold, impart a positive charge to the neutral charge of
the scaffold, and would enhance cell adhesion to the surface. A comparison of cells
grown on 3P vs. 3P/chitosan composite scaffolds showed that LLC-1 cells proliferated
but did not form tumoroids on 3P/Chitosan scaffold while cells cultured on the 3P
scaffold formed tumoroids at day 3 and continued to day 5. (Fig.2.24).
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MCF-10A

B16

MDA-MB-231

MCF-7

BG-1

Figure 2.21. Growth of other cancer cells as tumoroids on 3P scaffold. All of the
cancer types cultured on the 3P scaffold grew tumoroids. Breast cancer cells, MCF-10A
(5x103 cells/scaffold) at day 5, MDA-MB-231 (5x103 cells/scaffold) at day 4, MCF-7
(7x103 cells/scaffold) at day 5, B16 melanoma (5x103 cells/scaffold) at day 5 and BG-1
ovarian cancer (5x103 cells/scaffold) at day 5 grew tumoroids. Cells were stained with
calcein AM/EthD-1. Scale bar =50µm.

PLGA/PEG

PLGA

3P

Figure 2.22. Absence of tumoroid formation on scaffolds. LLC-1 cells
(5x103/scaffold) proliferated on PLGA/mPEG scaffolds but did not form tumoroids
similar to that observed on PLGA scaffolds, while tumoroids formed on the 3P scaffold
(day 4). Cells were stained with calcein AM /EthD-1 to detect live (green) and dead (red)
cells. Scale bar =50µm.
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Figure 2.23. Effects of topography on tumoroid formation: LLC-1 cells were
cultured on 3P and mPEG/PLA films (5x104) and on 3P scaffolds (5x103) from day 3 to
day 5. Cells were stained with calcein AM/EthD-1 to detect live (green) and dead (red)
cells. Cells on the 3P film formed tumoroids that easily dissociated along with the film on
day 5. Cells on the mPEG/PLA film grew into large disorganized aggregates that lacked
the shape and structure of a tumoroid and also dissociated by day 5. Cells on the 3P
scaffold formed tumoroids on day 3 and continued to day 5. Scale bar =500µm.
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3P/
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Figure 2.24. Effects of charge on tumoroid formation. LLC-1 cells were cultured
from day 2 to day 4 on the 3P/chitosan composite scaffold. Chitosan imparted a net
positive charge to the neutral scaffold at physiological pH. Cells grew on the
3P/chitosan composite scaffold but did not form tumoroids demonstrating better cellscaffold over cell- cell interactions. Cells cultured on the 3P scaffold formed tumoroids
on day 3 and day 4. Cells were viewed by SEM and calcein AM/EthD-1 staining. Scale
bar =50µm.
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Cell migration from tumoroids onto tissue culture plate
LLC-1 tumoroids that were transferred from the 3P scaffold to a regular tissue culture
plate adhered to the plate and migrated out from the tumoroid underscoring the
importance of 3P topography in tumoroid formation. LLC-1 cells gradually migrated
away from the tumoroid on day 2 and ultimately formed a confluent monolayer by day 4
(Fig.2.25). Tumoroids transferred to new scaffolds however maintained their
morphology and shape over the same time period.

Day 0

Day 2

Figure 2.25. Tumoroids cultured on tissue culture plate. Tumoroids (day10) were
transferred from the 3P scaffold onto tissue culture plate and cultured for two days.
Cells grew out from the tumoroid onto the plate starting at day 2. Top panel: phase
contrast image; bottom panel: cells stained with calcein AM/EthD-1 to detect live (green)
and dead (red) cells; side panel: close up view of cells migrating from the tumoroid to
the plate (day 2).
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Chapter Three
Tumoroids grown on 3P scaffolds mimic in vivo tumorigenesis

3.1 Introduction
The extracellular matrix is essential in directing numerous cellular processes during
cancer. Cells adhere and interact with their underlying ECM via integrins linked to focal
adhesions in their cytoskeleton. This represents the primary mechanotransductory axis
of the cell and enables cells to apply forces to the ECM as well as sense mechanical
perturbations emanating from the environment [133]. These interactions are similar
when cells are cultured on various 3D artificial scaffolds [134] [135]. Epithelial
mesenchymal transition (EMT) is a highly orchestrated and complex event involving the
integration of biochemical signals from integrins acting as ECM receptors, and growth
factor receptors such as transforming growth factor-β (TGFβ) and receptor tyrosine
kinases that activate Rho family of small GTPases [136-138]. TGF-β is the major
inducer of EMT and signals in a canonical manner to phosphorylate cytoplasmic SMAD
proteins that translocate to the nucleus and stimulate the EMT transcriptional program
or requires the activities of signaling pathways such as phosphatidylinositide 3kinases/protein kinase B pathway (PI3K/AKT) and the mitogen activated protein kinase
pathway (MAPK ), indirectly through transactivation in a non-canonical manner[139141]. PI3K signaling can be activated by integrins and members of the Rho GTPases
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that control cytoskeleton re-modeling, a major necessity during the morphogenic
process of EMT [142,143]. In response to changes in their environment, cells will
attempt to match their internal stress to the external environment. Increased cell
contractibility and conformational changes in response to stiffness can influence
biochemical signaling cascade via integrin clustering that induce the binding of RGD
sequences on the latent TGFβ receptor resulting in activation. The consequences lead
to the activation of EMT signaling pathways, the downregulation of E-cadherin and the
upregulation of mesenchymal genes [134,144,145]. These interactions suggest that
EMT can no longer be examined as a purely cellular event, but one that is affected by
the physical status of the microenvironment. At the biomaterial/cellular interface both
biochemical and mechanical cues from in vitro 3D scaffolds play a role in activating the
EMT program. It has been shown that breast cancer cells induce EMT when grown on
aligned electrospun fibers than on scaffolds consisting of random fibers [146]. The
formation of spheroids in 3D matrices further introduces pathophysiological cues that
may modify cancer cell fate towards a metastatic differentiated pathway. Considering
that 3P scaffolds induced tumor cells to form tumoroids that resemble micrometastatic
tumors, we determined whether LLC-1 tumoroids formed on 3P scaffolds could undergo
the EMT and compared these results with cells grown on PLGA scaffolds and in 2D
monolayer culture. We hypothesize that the novel 3P scaffold allows for the formation of
tumoroids that mimic in vivo tumorigenesis, observed by the induction of EMT. This was
shown by the expression of vimentin and the loss of expression of E-cadherin
suggesting that tumoroid formation correlate with enhanced invasive potential and
tumorgenicity, characteristics that define the EMT and that appear to be manifested

53

within the context of the 3P environment. EMT expression coincided with tumoroids
formation on the scaffold.

Epithelial mesenchymal transition (EMT)
EMT is a developmental program that regulates embryonic morphogenesis and involves
major phenotypic and molecular changes in cells. Experimental models reveal that EMT
is re-utilized during the re-epithelialization of wound healing and tissue fibrosis as well
as during tumorigenesis [147,148]. EMT occurs in oncogenically transformed cells that
house a variety of genetic and epigenetic abnormalities that conspire with the molecular
cascade that underlies EMT to elicit metastatic dissemination. As cancer evolves
towards metastasis, EMT imparts malignant features such as motility, invasion,
resistance to apoptosis and therapeutic drugs and the acquisition of stem- like
properties to cells [149-151]. Invasion is characterized by the loss of cell to cell contact,
loss of basolateral polarity and adherens junction, cytoskeleton rearrangement and
changes in the interactions of tumor cells with the extracellular matrix. This is as result
of the disruption and delocalization of tight junction complexes for example claudins and
zona occludins-1, and formation of actin stress fibers. This is succeeded by the loss of
E-cadherin expression and activity that results in the nuclear accumulation of β-catenin.

Loss of E-cadherin expression is the hallmark of EMT
The hallmark of EMT is the transcriptional repression of E-cadherin. It is a calcium
dependent transmembrane glycoprotein responsible for cell-cell adhesion, and
cytoskeleton organization. The loss of function has been associated with the
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progression of metastasis and poor prognosis in several cancers including prostate,
breast and lung [152,153]. The repression of E-cadherin is a consequence of the
association of transcriptional repressors with E-box sequences within the E-cadherin
promoter. Known transcription factors such as the snail family of zinc finger proteins
Zeb-1, Snail 1 and 2, and the basic helix-loop-helix protein Twist, form repressive
complexes in a sequential manner [154-157]. In various human carcinomas, functional
loss of E-cadherin results from the production of a defective protein, which may be a
result of gene mutation, abnormal post-translational modification (phosphorylation or
glycosylation) or increased proteolysis [158-160]. Besides its regulation by the
transcriptional repressors the E-cadherin gene expression can also be regulated at the
transcriptional level by silencing through promoter hypermethylation. In fact, E-cadherin
has been one of the first genes with promoter hypermethylation identified at very high
frequencies in human cancer specimen [161] . Concomitant with the loss of E-cadherin
is the expression of mesenchymal makers such as vimentin that is ubiquitously
expressed in mesenchymal cells as well as other markers such as smooth muscle actin
(SMA) and fibronectin.

EMT and the tumor stroma
During the progression into malignancy, EMT may be induced by a variety of stimuli,
including growth factor signal transduction pathways to the loss of E-cadherin functional
gene or protein degradation and mutation. Signal transduction pathways involving TGFβ, wingless-related integration site (WNT), PI3K/AKT, MAPK and Notch pathways
cooperate by crosstalk via growth factors and cytokines to effect repressor functions
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[162-164] . In many cancers, the tumor- stroma produces a variety of growth factors,
such as epithelial growth factor [165], platelet derived growth factor (PDGF) [166] and
fibroblast growth factor [167] and the most important inducer of EMT, TGF-β [168] that
are able to induce the transcriptional repressors of E- cadherin. For example,
hepatocyte growth factor (HGF) stimulates the EMT process by activating MAPK
signaling resulting in the activation of the transcription factor Egr-1 and the subsequent
expression of Snail-1 leading to the downregulation of E-cadherin gene expression
[169]. In addition to MAPK signaling, PI3K signaling plays a key role in inducing and
maintaining EMT. Cells expressing a constitutively active form of AKT, the most
important downstream effector of PI3K signaling, induced expression of Snail-1, which
in turn repressed E-cadherin gene transcription and induced EMT [170]. Furthermore,
autocrine PDGF receptor signaling in the presence of oncogenic Ras hyper activated
PI3K signaling which is required for cell survival during EMT [171]. TGF exercises two
opposing functions during cancer. In the early stages it functions as a tumor suppressor
by inhibiting proliferation and inducing apoptosis. However, in cells that have escaped
its pro-apoptotic effects, TGF enhances cell invasion, migration and evasion of immune
surveillance [172]. TGF-β is the major inducer of EMT and signals in a canonical
manner via two serine/threonine receptors to phosphorylate and form complexes with
cytoplasmic mothers against decanpentaplegic (SMAD) proteins that translocate to the
nucleus and stimulate the EMT transcriptional program. Upregulation of mesenchymal
genes such as Vimentin, Fibronectin, and matrix metalloproteinase are important
operands in bestowing migratory and invasive properties and are targeted by TGF-β.
The Notch pathway, crosstalks significantly with the TGF-β pathway via SMADs that
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upregulate the Notch receptor ligand Jagged 1, and induces cell cycle arrest. WNT
signaling elicits sequestration of glycogen synthase kinase that promotes the
stabilization of Snail further cooperating with other transcription factors to promote EMT.

EMT and stem cells
Empirical evidence connecting EMT to the emergence of stem cells has recently been
reported [173]. Pathophysiological conditions such as tumorigenesis can trigger
differentiated cells to acquire a multipotent stem-cell-like phenotype through EMT
induction [174]. Studies also indicate that metastatic cancer cells, which have
presumably undergone EMT, may exhibit a cancer stem cell (CSC) phenotype. For
instance, disseminated breast cancer cells found in pleural effusions are enriched for a
CD44high and CD24low CSC-like population [175]. In pancreatic tumors, CD133+
mesenchymal like cells that also express the chemokine receptor 4 (CXCR4) are found
predominantly at the invasive front of tumors where they may be primed for metastatic
spread [176]. A four-week period of exposure of immortalized human bronchial epithelial
cells to tobacco carcinogens has been shown to induce a persistent, irreversible, and
multifaceted dedifferentiation program marked by EMT and the emergence of stem celllike properties [177].

3.2 Methods
Immunofluorescence staining
Cells were washed three times with phosphate buffered saline (PBS) then fixed with 4%
paraformaldehyde in PBS for 20 minutes at room temperature, followed by
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permeabilization in 1.0% Triton X-100 for 15 minutes. They were then incubated with
1% bovine serum albumin (BSA) for 30mins at room temperature then incubated with
the primary antibody overnight at 4°C. They were washed three times with PBS then
incubated with the secondary antibody for one hour at room temperature in the dark.
The primary antibodies against vimentin (rabbit polyclonal) (Cell Signaling) were diluted
at 1:200 and E-cadherin (mouse monoclonal) (Santa Cruz Biotechnology) was diluted at
1:200. Secondary antibodies were goat anti-rabbit conjugated to Alexa 594 and goat
anti-mouse conjugated to Alexa 488 (Invitrogen). All antibodies were diluted in 1% BSA
[178]. Cells were washed three times with PBS then two drops of the mounting media
containing the nuclear stain 4’,6-diamidino-2-phenylindole (DAPI) (Vector Labs) were
added prior to covering with a glass coverslip and viewing on a fluorescent microscope.

3.3 Results
Tumoroids formation induce EMT
LLC-1 cells were cultured as monolayer or on PLGA and 3P scaffolds and examined for
EMT marker expression. Cells on the 3P scaffold formed tumoroids by day 3 that
expressed vimentin while none was observed in the monolayer culture or in cells
cultured on PLGA scaffolds. Additionally tumoroids exhibited a loss of E-cadherin
expression on 3P scaffolds and EMT. However cells cultured on monolayer or on PLGA
scaffolds retained E-cadherin expression and an absence of vimentin and no EMT
(Fig.3.1).
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Figure 3.1. EMT in LLC-1 tumoroids. LLC-1 cells (5x103) were cultured as monolayer,
or on PLGA or 3P scaffolds for three days, then fixed and immunostained with anti-Ecadherin (green), anti-vimentin (red) and DAPI (blue) for staining nuclei. (A) LLC-1 cells
on PLGA scaffolds and on monolayer showed E-cadherin expression while cells cultured
on the 3P scaffolds that formed tumoroids by day 3 did not express E-cadherin. (B) Cells
on PLGA scaffolds and on monolayer showed no vimentin expression while tumoroids
on the 3P scaffold showed vimentin expression. Cells cultured on monolayer and PLGA
scaffold showed no EMT while EMT correlated with the formation of tumoroids on the 3P
scaffold. Scale bar= 20 µm.
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Timeline of EMT
To determine the timeline of EMT induction, LLC-1 cells were cultured on 3P scaffolds
and stained for vimentin and E-cadherin expression from day1 to day 4. From day 1 to
day 2 cells did not form tumoroids. E-cadherin expression was observed but there was
an absence of vimentin expression indicating the absence of EMT. However it was
observed that cells begin to form tumoroids beginning at day 3 and there was a loss of
E- cadherin expression and a gain in vimentin expression that signified the onset of
EMT. Tumoroid formation and EMT induction continued into day 4. The timeline of EMT
coincided with the self-assembly of the cells into tumoroids (Fig.3.2).

EMT in other tumoroids
All of the cell lines that formed tumoroids on the 3P scaffolds expressed EMT markers.
EMT correlated with tumoroid formation on the 3P scaffold. Cells cultured on monolayer
for each of these cell lines showed E-cadherin expression and the absence of vimentin
and no EMT. However, with the formation of tumoroids, EMT marker expression was
observed. PC3 (human prostate cancer) expressed EMT markers at day 5, B16 (mouse
melanoma) at day 5, MCF-7 at day 7, and MDA-MB-231 (human breast cancer) at day
4 cells (Fig.3.3). LLC-1 cells cultured on 3P/chitosan composite scaffolds did not form
tumoroids and there was an absence of EMT marker expression, however cells cultured
on the 3P scaffold formed tumoroids and were positive for EMT (Fig.3.4).
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Figure 3.2. Timeline of EMT. LLC-1 cells (5x103) were cultured on 3P scaffolds from
day 1 to day 4 and immunostained with anti-E-cadherin (green), anti-vimentin (red) and
DAPI (blue) for staining nuclei. (A) E-cadherin expression was observed in cells cultured
in day 1 and day 2 but absent in tumoroids that started to form in day 3 and continued to
day 4. (B) Cells cultured from day 1 to day 3 showed no vimentin expression but there
was vimentin expression in tumoroids formed in day 3 and continued to day 4. EMT
coincided with the onset of tumoroid formation at day 3. Scale bar =20µm.
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Figure 3.3. EMT in other tumoroids. B16 melanoma, BG-1 ovarian cancer, MCF -7
breast cancer, MDA-MB 231 breast cancer and PC3 prostate cancer cells were cultured
on monolayer and 3P scaffold, then were fixed and immunostained with anti-E-cadherin
(green), anti-vimentin (red) and DAPI (blue) for staining nuclei. Cells cultured on
monolayer showed E-cadherin expression, no vimentin expression and absence of
EMT. Cells on the 3P scaffold formed tumoroids and showed vimentin expression while
no expression of E-cadherin was observed. B16 tumoroids expressed EMT markers at
day 5, BG-1 at day 5, MCF-7 at day 7, MDA-MB-231 at day 4 and PC3 at day 5. Scale
bar =20 µm.
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Figure 3.4. Absence of EMT in 3P/chitosan tumoroids. LLC1 cells (5x103) were
cultured on 3P/chitosan composite scaffold or 3P scaffold for 3 days, then
immunostained with anti-E-cadherin (green), anti-vimentin (red) and DAPI (blue) for
staining nuclei. Cells on the 3P/chitosan composite scaffold did not form tumoroids and
showed expression of E-cadherin, the absence of vimentin expression and EMT. Cells
on the 3P scaffold formed tumoroids and showed the absence of E-cadherin
expression, the presence of vimentin and EMT induction. Scale bar = 20µm.
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Chapter 4
The 3Pscaffold can be used to assess chemotherapeutic efficacy and serve as a
platform for the growth of tumor biopsies3

4.1 Introduction
Three-dimensional (3D) culture systems such as the 3P scaffold, that mimic the tumor
microenvironment may serve as optimal tools for drug screening. An eventual goal for
such systems is to include the ability to incorporate individual patient tumor biopsies to
test patient-specific responses to chemotherapeutic drugs and produce responses more
predictive of clinical efficacy. The use of these 3D systems could improve drug testing in
at least two ways: 1) speed decision-making for whether a particular therapeutic agent
is worth pursuing thereby reducing time, cost and pain to the patient and 2) lead to
fewer trial failures because of faster, more relevant results.Tumoroids represent
physiologically relevant platforms for drug screening because they mimic the
micrometastasis of tumors. With increasing size, they develop regions of hypoxia and
central necrosis that have been shown to cause drug resistance [179,180]. They exhibit
chemical gradients and mass transport limitations that are spatially correlated with

3

A portion of this chapter have been previously published by the author in an article
entitled “A 3D Fibrous Scaffold inducing Tumoroids: A Platform for Anticancer Drug
Development”, PlosOne, October 16 2013, Vol.8, Issue 10 and have been reproduced
with permission from the publishers.
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cellular physiology and are associated with alterations in sensitivity to a wide variety of
anti tumor agents. In addition the sphere like symmetry may allow for simple theoretical
analysis for the prediction of, for example, drug penetration and binding. The cell-cell
interactions via cytoskeleton proteins such as tight junctions and the consequent signal
transduction communication have been found to influence the response of cells to drugs
[181]. Tumoroids are amenable to co-culture of different cell types and it has been
shown that different cellular fractions in the tumoroid affect behavior and response to
drugs similar to that observed in vivo [182]. Cocultured tumoroids may provide a model
for deciphering the responses of different cell types to drug resistance in vivo. Our goal
is to produce a 3D culture system that is validated against known effective anticancer
agents to demonstrate the system's utility as a predictive tool and screening assay. We
hypothesize that the 3P tumoroids can be used to assess chemotherapeutic efficacy,
support the growth of biopsy tumoroids and can be utilized to culture primary patient
samples for personalized drug therapy. Both PI3K and MAPK pathways have been
implicated in EMT in cancer cells. The inhibitors, such as LY294002 that inhibits the
PI3K pathway and U0126 that inhibits the MAPK pathway, are control modulators of
EMT and have shown broad antiproliferative activity amongst tumor cell types including
melanoma, liver and breast cancer cells [183-186] [187,188]. We show that 3P
tumoroids treated with antitumor agents LY294002 and U0126 inhibitors displayed a
dose dependent cytotoxic response. Thus, our results demonstrate that the 3P
tumoroids can be used to assess chemotherapeutic efficacy in both prevention and
treatment modalities using the inhibitors. Finally, we evaluated the possibility of
generating 3P tumoroids from tumor biopsy specimens of mice and testing them for
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anticancer drug sensitivity. Tumor-stroma interactions affect cancer growth, metastasis
and the acquisition of drug resistance. 3P scaffolds supported the growth of both tumor
and stromal cells. Our results show that 3P scaffolds can be used both to study the
mechanism of tumorigenesis and to evaluate anticancer drugs in the arena of
individualized and patient specific therapy.
Antiproliferative drugs Ly29402 and U0126
Both MAPK and PI3K/AKT signaling pathways are known regulators of tumor invasion
and EMT. For example, growth factors such as HGF stimulates the EMT process by
activating MAPK signaling resulting in the activation of the transcription factor, Snail-1,
leading to the transcriptional repression of E-cadherin gene expression, the hallmark of
EMT. Additionally it has been shown that cells expressing a constitutively active form
of PKB/AKT, the most important downstream effector of PI3K signaling, induce
expression of Snail-1, which in turn represses E-cadherin gene transcription and
induces EMT. The PI3K pathway inhibitor LY294002 and MAPK pathway inhibitor
U0126 have shown broad anti proliferative activity amongst many tumor cell types
including MDA-MB468 and ZR-75 breast cancer, and 451LU and SKMEL 28
melanoma cell lines [189,190]. LY294002 inhibits the PI3K/AKT pathway by
dephosphorylation of AKT thereby inducing G1 arrest followed by apoptosis. U0126
selectively inhibits MEK a dual specificity kinase in the MAPK cascade from
phosphorylating ERK1/2 and prevents activation leading to apoptosis.
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4.2 Methods
Inhibition of tumoroid formation and IC-50 determination
MCF-7 cells were cultured in 3P scaffolds at a cell density of 7 x103 /scaffold for two
days in complete medium. The culture medium was carefully removed and replaced
with 100 µl of fresh media with LY294002 (at concentrations 0.0 µM, 0.1µM, 1.0µm and
10µM) or U0126 (at concentrations 0.0nM, 10nM, 100nM, and 1000nM). Cells were
incubated for three days in a humidified atmosphere under 5% CO2/95%air at 37°C then
stained with calcein AM / EthD-1 stain. The viable cell number was counted using the
ImageJ software. The cell viability was estimated by dividing the treated viable cells by
untreated viable cell number. The IC-50, the concentration of drugs required to inhibit
50% cell growth was calculated from the dose response curve using GraphPad Prism
Software (version 5.01).

Treatment of established tumoroids with inhibitors
For evaluating effects of inhibitors on established tumoroids, LLC-1 cells were seeded in
the 3P scaffolds at a cell density of 5x103/scaffold and cultured for four days in complete
DMEM media to allow for tumoroid formation. The culture media was replaced with
fresh media containing different concentrations of the LY294002 inhibitor (0.0µM,
0.01µM, 0.1µM and 1.0µM) and U0126 inhibitor (0.0nM, 1.0nM, 10nM and 100nM). The
media were replaced with fresh media or media containing the drugs every two days.
Tumoroids were stained with calcein AM/EthD-1 at 24hrs, 48hrs and 96hrs posttreatment and evaluated for tumoroid size and numbers.
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Celltracker staining
MCF-7 tumoroids cultured on the scaffolds for 7 days were washed with PBS twice.
Celltracker Green (0.3125uM) in serum free media was added to scaffold and incubated
at 370C for 15 mins. The solution was removed and the scaffolds were incubated in
serum-free media at 370C for 30 minutes. The scaffolds were placed in a glassbottomed dish containing a 10uM solution of doxorubicin and timed uptake of the drug
was observed using an Olympus 1X81 inverted microscope with a microcell culture
chamber attached. Images were taken using a 60X water lens. Celltracker green was
excited at 488nm and collected with a 525/50-band pass emission filter. Doxorubicin
was excited at 488 and emission collected with a 617/73 nm band pass filter. Serial
images (20 slices, 6 tumoroids) were taken at half hour intervals up to four hours until
nuclear uptake of the drug was observed in both monolayer and tumoroid cells.

Culturing fine needle aspirates (FNAs) of implanted mouse tumors
LLC-1 cells (5x105) were subcutaneously injected into the flanks of wild type C57BL/6
mice (National Cancer Institute). Tumor formation was monitored for two weeks after
which tumor biopsies were collected as FNAs. Briefly, a 23 gauge needle was inserted
into the tumor using a rotating motion and the tissue samples were flushed from the
needle by attaching a syringe filled with tissue culture medium and expelling the
contents into a sterile tube. This process was repeated twice. The three collected tumor
samples were pooled and single cell suspensions were cultured on the scaffold.
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Immunofluorescence staining
For dual immunostaining, biopsy tumoroids were incubated with the first primary
antibody in 1% BSA in phosphate-buffered saline plus Tween 20 (PBST) overnight at
4°C, washed three times with PBS, and incubated with the corresponding secondary
antibody in 1% BSA in PBST for one hour at room temperature in the dark. After
washing three times with PBS, cells were blocked for a second time with 10% serum
from the species the secondary antibody was raised for 30 minutes at room
temperature. Cells were then incubated with the second primary antibody in 1% BSA in
PBST overnight at 4°C, followed by the second secondary antibody in 1% BSA for 1 hr
at room temperature. The cells were stained with the nuclear stain DAPI and imaged
with a fluorescent microscope. Carcinoembryonic antigen (CEA) antibody (mouse
monoclonal) (GeneMed) was used at 1:200, CD31 (mouse monoclonal) (Abcam) at
1:50, F4/80 (rat monoclonal) (Abcam), SMA (goat polyclonal) (Abcam) at 1:100
dilutions, Vimentin (rabbit polyclonal) ( Cell Signaling) at 1:200 and E-cadherin ( mouse
monoclonal) ( Santa Cruz) at 1:200 dilutions [132]. Secondary antibodies were goat
anti-mouse conjugated to Alexa 594, (Invitrogen), rat anti-mouse conjugated to Alexa
488, goat anti-rat conjugated to Alexa 488, and donkey anti-goat conjugated to Alexa
488, goat anti-rabbit conjugated to Alexa 594 and goat anti-mouse conjugated to Alexa
488 (Invitrogen). Secondary antibodies were diluted 1:100 in 1% BSA.

4.3 Approval declaration for animal studies.
All animal studies were approved and conducted according to guidelines of the
University of South Florida Institutional Animal Care and Use Committee.
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4.4 Statistical analysis
Quantitative data were expressed as mean +/- standard deviation. Student’s t-test was
used to analyze the statistical significance of the data between groups. Values with p<
0.05 were considered statistically significant. All experiments were performed in
triplicate.

4.5 Results
Prevention of tumoroid formation by inhibitors
To test the feasibility of the 3P scaffold to assess drug sensitivity, we examined the
effects of known antitumor agents as control modulators of EMT. First, to evaluate if
treatment can prevent tumoroid formation, MCF-7 cells were cultured on 3P scaffolds in
the presence or absence of the LY294002 or U0126. Both inhibitors prevented tumoroid
formation but cells that were untreated formed tumoroids (Fig.4.1). Cells that were
treated with inhibitors showed the presence of E- cadherin expression and the absence
of vimentin indicating the absence of EMT while cells that were untreated formed
tumoroids and were positive for vimentin expression and an absence of E-cadherin and
were positive for EMT (Fig.4.2).

IC-50 determination
Cells were treated with LY294002 and U0126 inhibitors at day 2 of culture before
tumoroids were formed. The cells were incubated with or without the inhibitors for 3
days then cells the were stained with calcein AM/EthD-1. The viable cell number was
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counted using the ImageJ software. The cell viability was estimated by dividing the
treated viable cells by untreated viable cell number and the IC-50 was calculated from
the dose response curve using GraphPad Prism Software .Scaffold-grown MCF-7 cells
showed reduced sensitivity to inhibitors compared to cells on monolayer, as determined
by the IC-50. The IC-50 of LY294002 for the monolayer was 0.1µM and for the 3P
scaffold was 1.092 µM. Similarly, the IC50 of U0126 on the monolayer and 3P scaffold
was 6.72 nM and 652 nM, respectively (Fig.4.3).

Treatment with LY294002 inhibitor
Our second approach was to determine if these inhibitors were effective in modulating
established tumoroid growth. Formed LLC-1 tumoroids (day 3) were treated with various
concentrations of Ly294002 for 24hrs, 48hrs and 96 hrs then assessed for changes in
diameter and numbers. Measurements of tumoroid size and numbers revealed a dosedependent cytotoxicity in treated tumoroids compared to untreated tumoroids. With
increasing concentration of drugs, we observed more cell death accompanied with the
dissolution of the tumoroids (Fig.4.4A). At 24 hours, tumoroids treated with LY294002 at
concentration of 0.01µM, 0.1µM and 1.0µM demonstrated an average decrease of 17%,
22% and 37% in size respectively compared with untreated tumoroids. At 48 hours post
treatment tumoroid size decreased on average 29%, 33% and 51% respectively and at
96 hours post treatment, those treated with 0.01 µM decreased 63% while those treated
with1.0 µM and 0.1µM of inhibitor appeared dead. Tumoroid numbers decreased
significantly from 14%, 26% and 37% respectively at 24hrs post treatment to 40%, 53%
and 62% respectively at 48hrs. Tumoroids treated with 0.01µM inhibitor decreased by
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93% while tumoroids treated with 1.0uM, 0.1uM of inhibitor dissipated at 96 hours after
treatment. (Fig 4.4B).

Control

LY294002

U0126

Figure 4.1. Inhibition of tumoroid formation. MCF-7 breast cancer cells were
cultured for 2 days on the 3P scaffold then treated with 1µM LY294002 and 100nM of
U0126 for three days. The inhibitors prevented tumoroid formation on treated cells while
untreated control cells grew tumoroids. Scale bar =50µm.

Control

E-Cad/Vim

LY294002

E-Cad/Vim

U0126

E-Cad/Vim

Figure 4.2. Inhibition of tumoroid formation abrogates EMT. MCF-7 cells were
cultured on the 3P scaffold for two days then treated with 1µM LY294002 and 100nM
U0126 for three days. Cells were immunostained with anti-E-cadherin (green), antivimentin (red) and DAPI (blue) for staining nuclei. Cells that were treated with the
inhibitors showed the presence of E-cadherin and the absence of vimentin and were
negative for EMT. Untreated cells formed tumoroids that were positive for EMT markers.
Scale bar = 20 µm.
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Figure 4.3. Cytotoxicity response of MCF-7 cells to inhibitors. MCF-7cells were
cultured on monolayer and 3P scaffolds for two days then treated or not treated with
LY294002 or U0126 inhibitors. Cells were incubated for three days then stained with
calcein AM / EthD-1. The IC-50 was calculated from the dose response curve using
GraphPad Prism software. Cells cultured on the 3P scaffold demonstrated more
resistance to the LY294002 and U0126 than cells cultured on monolayer. The IC-50 for
cells treated with LY294002 on the 3P scaffold was1.092 µM and on monolayer 0.1 µM.
The IC50 for cells treated with U0126 on the 3P scaffold was 652 nM and for cells
cultured on monolayer 6.72 nM. Data is presented as mean +/- SD, n= 4 scaffolds/
concentration of drugs. Experiments were performed in triplicates.

Treatment with U0126 inhibitor
LLC-1 tumoroids treated with U0126 followed a similar trend. LLC-1 tumoroids (day 3)
were treated with different concentrations U0126 for 24hrs, 48hrs and 96 hrs then
assessed for changes in tumoroid diameter and numbers. With increasing concentration
of drugs, we observed more cell death accompanied with the dissolution of the tumoroids
(Fig.4.5A). At 24 hours, tumoroids treated with U0126 at concentration of 1.0 nM, 10nM
and 100nM demonstrated an average decrease of 18%, 30% and 35% in size
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respectively compared to untreated tumoroids. At 48 hours post treatment tumoroid size
decreased on average 35%, 45% and 51% respectively and at 96 hours post treatment,
those treated with 1.0 nM and 10nM decreased 60% and 80% respectively while those
treated with100nM of inhibitor appeared dead. Tumoroid numbers decreased from 29%,
30% and 43% respectively at 24hrs post treatment to 45%, 45% and 51% respectively at
48hrs. Tumoroids treated with 1.0 nM and 10nM inhibitor decreased by 71% and 88%
while spheroids treated with 100nM of inhibitor dissipated at 96 hours post treatment
(Fig.4.5B).
Diffusion of doxorubicin into 3P tumoroids
It has been proposed that decreased sensitivity to anticancer drugs in tumoroid cultures
may be attributed to factors related to micro-environmental mechanisms operating at the
multicellular level as well as a function of the synthetic in vitro 3D conditions. Since these
factors may limit drug penetration into the interior of the spheroid we utilized the intrinsic
auto florescent ability of doxorubicin to evaluate if diffusion limitations were a factor in
drug resistance. After incubating MCF-7 tumoroids on the 3P scaffold and on monolayer
in the presence of doxorubicin, it was observed that the drug completely penetrated the
tumoroid in 3 hours compared to monolayer that took two hours (Fig.4.6) suggesting
that drug resistance in the 3P system cannot merely be explained by effects on drug
transport.
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Figure 4.4. LY294002 induced cell death in LLC-1 tumoroids. (A) LLC-1 tumoroids
(day 4) were exposed to various concentrations of LY294002 for the indicated days and
then stained with calcein AM/EthD-1.Significant cell death with the dissipation of
tumoroids occurred at 96 hrs post-treatment. Scale bar =50µm. (B) The average change
in tumoroid size and numbers compared with untreated tumoroids show systematic
decrease in tumoroid numbers and diameter and total cell death by 96 hrs posttreatment. The data is presented as mean + SD (n= 4 scaffold /time point and 5
tumoroids/scaffold); * p<0.05.
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Figure 4.5. U0126 induced cell death in LLC-1 tumoroids. (A) LLC-1 tumoroids (day
4) were exposed to various concentrations of U0126 for the indicated days and then
stained with calcein AM/EthD-1. Cell death and dissipation of tumoroids occurred at 96
hrs post-treatment. Scale bar =50µm. (B) The average change in tumoroid size and
numbers compared with untreated tumoroids show gradual decrease in tumoroid
numbers and diameter and total cell death by 96 hrs post-treatment. The data is
presented as mean + SD (n= 4 scaffold /time point and 5 tumoroids/scaffold); * p<0.05.
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Figure 4.6. Diffusion of doxorubicin into MCF-7 tumoroids. MCF-7 tumoroids and
monolayer cells were treated with 10µM doxorubicin and observed for timed uptake of
the drug by confocal microscopy. Cells (green) were stained with CellTracker dye.
Utilizing the intrinsic autoflourescence ability of doxorubicin the drug appears red in the
nucleus using the red filter of the confocal microscope. Doxorubicin completely diffused
into the nuclei of the monolayer cells in 2 hours and the tumoroid in 3 hours.

Treatment with inhibitors abrogates EMT
To determine if treatment with these inhibitors inhibited EMT in fully formed tumoroids,
we administered the same concentrations of the drugs to tumoroids cultured for four day
on the 3P scaffold. Results showed that after 48hrs, treatment with LY294002 and
U0126, EMT was abrogated. This was demonstrated by the absence of vimentin and
the presence of E-cadherin expression (Fig.4.7). Control tumoroids that were not
treated by the inhibitors showed vimentin expression and the absence of E-cadherin
and were positive for EMT. These findings implicate both PI3K and the MAPK signaling
as significant contributors to tumoroid formation and EMT on 3P scaffolds.
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Growth of biopsy tumoroids
To determine if the 3P scaffold can be utilized to culture tumor biopsies, single-cell
suspensions of FNAs of implanted mouse tumors were cultured on 3P scaffolds. The
average diameter increased from day 1 to day 5 was 152.29µm to 287.5 µm at
approximately the same rate observed in the experiments with tumor cell lines.
Immunostaining of biopsy tumoroids showed loss of expression of E-cadherin and gain
of expression of vimentin and EMT induction (Fig. 4.8).
Presence of tumor stroma in biopsy tumoroids
Biopsy tumoroids were examined for the presence of stromal cells that are typical of the
in vivo tumor microenvironment by immunostaining with antibodies to respective cell
surface markers. Biopsy tumoroids were found positive for CEA and the stromal cell
markers CD-31, F4/80 and SMA. LLC-1 tumoroids, used as control expressed only
CEA (Fig.4.9).
Chemosensitivity of tumor biopsy grown on 3P scaffolds
To determine if the biopsy tumoroids cultured on 3P scaffolds can be utilized to assess
chemotherapeutic efficacy, FNA tumoroids were cultured in the presence or absence of
the inhibitors, LY294002 and U0126. Results showed that inhibitors were effective in
modulating biopsy tumoroid growth as revealed by decrease in tumoroid size Fig.4.10).
However, the IC50s of LY294002 and U0126 were >1uM indicating a greater resistance
of biopsy tumoroids to the drugs than LLC-1 tumoroids. drugs than LLC-1 tumoroids.
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Figure 4.7. EMT in tumoroids treated with inhibitors. LLC-1 tumoroids were treated
with LY294002 (1 µM) and U0126 (100nM) for 48hrs then immunostained using anti-Ecadherin (green), anti-vimentin (red) and DAPI (blue). (A) Untreated control tumoroids
expressed vimentin while tumoroids treated with the inhibitors showed no expression of
vimentin. (B) Untreated control tumoroids lacked E-cadherin expression while tumoroids
treated with the drugs showed expression of E-cadherin. The inhibitors abrogated EMT
in the treated tumoroids while untreated tumoroids expressed EMT markers. Scale
bar=50µm.
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Figure 4.8. Biopsy tumoroids on 3P scaffolds. (A) Biopsy tumoroids were cultured on
the 3P scaffolds from day 1 to day 3. Cells were stained with calcein AM/EthD-1. Scale
bar =200 µm. (B) The average size of biopsy tumoroids ranged from 152µm to 288 µm
respectively. Data represents mean+/- SD, n= 12 tumoroids/ timepoint. (C) Tumoroids
(day 3) were fixed and immunostained using anti-E-cadherin (green), anti-vimentin (red)
and DAPI (blue). Tumoroids showed the absence of E-cadherin expression and the
presence of vimentin expression and were positive for EMT. Scale bar =100µm.
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Figure 4.9. Tumor stroma in tumor biopsies. Biopsy tumoroids (day 3) stained
positive for tumor cell marker CEA), macrophage marker F4/80, endothelial progenitor
cell marker CD-31 and cancer-associated fibroblast marker SMA, indicating the
presence of stromal components in the tumoroids. LLC-1 cell line tumoroids, used as
control expressed only CEA. CEA was stained red, CD31, F4/80 or SMA stained green,
and DAPI (blue). Scale bar=100µm.
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Figure 4.10. Chemosensitivity of biopsy tumoroids. (A) Biopsy tumoroids were
cultured on the 3P scaffold and treated with 1uM of LY294002 or U0126 for 3 days.
Tumoroids displayed a dose dependent cytotoxicity in response to the drugs. The size
of biopsy tumoroids decreased by 37.3% after treatment with LY294002 and 56% after
treatment with U0126.This was compared with untreated control tumoroids. (B) Calcein
AM/EthD-1 staining of biopsy tumoroids after treatment show live cells (green) and dead
cells (red). Scale bar =200µm. Data represent mean+/- SD (n= 10 controls, 55
LY294002 and 50 U0126) * p<0.05.

82

Chapter 5
Discussion and conclusion4

In this study, we report on a novel 3P fibrous scaffold that induced the formation of a
micrometastatic compact aggregate of tumor cells that we term a tumoroid. Our platform
has several advantages over existing 3D technologies. (1) The 3P fibrous scaffold is
produced from FDA-approved synthetic polymers. (2) It is conveniently and cheaply
manufactured by electrospinning, which creates a mat of randomly distributed nano- to
micro-scale fibers and can permit scale up production. (3) The scaffold mats can be cut
into smaller pieces for placement in the wells of standard plastic cell-culture dishes. (4)
Cancer cells seeded onto these scaffolds with growth medium containing the
appropriate factors grow as tumoroids that show the EMT characteristic of in vivo
tumorigenesis. (5) This platform allows the coculture of tumor cells and stromal cells to
identify changes in specific factors, gene expression and invasion potential. Tumoroids
are able to respond to the same biochemical, nanotopographical and mechanical cues
that drive tumor progression in the native ECM. (6) The 3P platform can be used to
evaluate therapeutic strategies for simultaneously targeting tumor cells and the stromal
cells that are components of the stem cell niche. (7) The 3P platform can also be
4

A portion of this chapter have been previously published by the author in an article
entitled “A 3D Fibrous Scaffold inducing Tumoroids: A Platform for Anticancer Drug
Development”, PlosOne, October 16 2013, Vol.8, Issue 10 and have been reproduced
with permission from the publishers.
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adapted for use in a point-of-care device to culture a patient’s own cells from a biopsy,
test them ex vivo with different anticancer compounds and tailor a personalized
treatment. Scaffold construction required systematic progression from the first PLGA
scaffold that provided the blueprint for the appropriate topographical and physical
features, to chemical modifications and final optimization to produce the 3P scaffold. To
create a 3D surface that mimics the in vivo tumor microenvironment we utilized
electrospinning to produce the 3P scaffold that induced all of the cancer cells used in
this experiment, to self-assemble into tumoroids. Although the mechanisms are
presently unknown there are two possibilities: (i) cell-cell interaction leading to tight
aggregates that form the tumoroids, and (ii) outward proliferation of a fiber-attached cell
to form a tumoroid. These possibilities are not mutually exclusive. Electrospun fibrous
mats mimic ECM structures and the pore size, diameter and thickness of the fibers may
regulate cell behavior [191]. Further, scaffold topography and architecture have been
shown in previous studies to influence tumor cell behavior [45,84,85,192-194]. The 3P
scaffold is composed of random fibers of a mixture of PLGA and PLA-PEG blockcopolymer. While PLGA and PLA possess good mechanical properties, controlled
degradability, and excellent biocompatibility [195-197], PEG alters the electrostatic
binding properties of cells and promotes cell-cell interactions leading to assembly of
tumoroids [9,198-200]. Although not fully elucidated, these characteristics may explain
the spatial and temporal forces required to trigger tumoroid formation on the 3P
scaffold. When we cultured LLC-1 lung cancer cells on the 3P scaffold they formed
tumoroids that persisted, while cells cultured on the same polymer deposited as a film
formed tumoroids that quickly disassociated. We also found that similar-sized scaffolds
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of PLGA did not form tumoroids, underscoring the contribution of PEG-PLA block
copolymer in the fiber, which by itself is not amenable to electrospinning. We changed
the scaffold from a neutral charge to a positive charge by surface modification with
cationic chitosan; this would increase the hydrophilicity and improve cellular interactions
with scaffold. However cells proliferated on the scaffold but did not form tumoroids
possibly because of strong preferential interactions of cells to the positive amine groups
on the scaffold over cell- cell interactions required to form tumoroids. Moreover, tumor
cells migrated from 3P tumoroids that had been transferred from the scaffold to tissue
culture plates. These results showed that chemical and physical cues from the 3P
scaffolds contributed to tumoroid formation. Tumoroid on 3P scaffolds underwent EMT
with a loss of E-cadherin expression, a condition that imparts invasive and migratory
capacity to cells and poor prognosis in several cancers [152,153]. Concomitant with
down-regulation of E-cadherin was the expression of vimentin, a major cytoskeleton
protein ubiquitously expressed in mesenchymal cells and tumor cells undergoing
metastasis [202,203]. Tumor cells cultured as monolayer or on unmodified PLGA
scaffolds maintained epithelial marker expression and did not undergo EMT. The
majority of in vitro studies of EMT involve cultured cells that are induced either by forced
expression of selected transcription factors or prolonged exposure to inducers such as
growth factors and cytokines, whereas in our experiments the EMT occurred as a
consequence of tumoroid formation. The EMT is considered an early event in the
metastatic process and studies have suggested that dissemination may occur prior to
tumor development [204,205]. In most experimental systems, a complete change in
EMT marker expression requires ten days or longer [148]. Expression of EMT markers
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by LLC-1 tumoroids on the 3P scaffolds occurred at day three of culture. The 3P
scaffold may supply physicochemical cues that trigger the EMT by altering cell-cell and
cell-matrix interactions, promoting architectural reorganization, or affecting the binding
of proteins to cell surface receptors involved in signal transduction pathways [9,198200]. It has been shown that pathways involving PI3K/AKT, MAPK and TGF-β
communicate via growth factors and cytokines to repress E-cadherin and up-regulate
mesenchymal genes during EMT [206]. TGF-β is the major inducer of EMT and acts
through canonical and noncanonical pathways to affect PI3K/ AKT, MAPK signaling
[164,207]. In support of this observation, we found that treatment of cancer cells with
LY294002 (PI3K inhibitor) and U0126 (MAPK inhibitor) prevented tumoroids
underscoring the importance of EMT in in vitro tumoroid formation.Treatment of
tumoroids with the PI3K pathway inhibitor Ly294002 or the MAPK pathway inhibitor
U0126, on 3P scaffolds vs. monolayer culture showed higher drug resistance of MCF-7
cells on the scaffold. The IC-50 values for 3P cultures were 10-fold higher for Ly294002
inhibitor and 100-fold higher for U0126 inhibitor than for monolayer cultures. These
results are supported by other studies showing that tumor cells grown as 3D tumoroids
develop multicellular resistance to most cytotoxic drugs compared to those grown in
monolayer culture [16,215]. For example, the in vivo drug-resistant variant, EMT-6, of
mouse mammary tumor cells lost resistance when cultured as a monolayer but regained
it when regrown in vivo as a solid tumor or in vitro as tumoroids [216]. The reasons for
the differences between 3D and monolayer cultures remain unknown.
Pathophysiological gradients to nutrients, oxygen and drugs and the concentric
arrangement of heterogeneous cell populations within the 3P tumoroids may affect RNA
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and protein expression. For example, it has been reported that quiescent cells near the
necrotic core of a tumoroid up-regulate the cyclin-dependent kinase inhibitor p27Kip1,
which arrests cells in the G0/G1 phase and induces cell cycle resistance [217]. The
expression of p27Kip1 is fifteen times greater in tumoroid culture than in monolayer
culture. In addition, inhibition of apoptosis via the Bcl-2 pathway [218], and the downregulation of PMS2 and topoisomerase 11 DNA mismatch repair proteins [219,220]
have been proposed as mechanisms that desensitize tumor cells in tumoroids to
antitumor agents. We showed that this resistance was not a result of a mass transport
defect. This is consistent with other drug penetration data that have shown that despite
efficient drug penetration, tumoroids still exhibit higher drug resistance than monolayer
cultures [221,222]. There is growing recognition that mechanical aspects, such as
applied forces or the rigidity of the ECM, crucially influence cellular behavior and
function in the induction of EMT [208] . These interactions are observed in vivo as well
as in vitro on 3D artificial substrates. To cope with the constant mechanical stress, cells
evolved specialized mechanosensing mechanisms. Several proteins undergo
conformational changes in response to applied force, including mechanically gated ion
channels [209], the cytoskeleton network [210], and ligand–receptor binding [211].
Integrins interact with both the ECM and focal adhesion proteins and function as
ubiquitous mechanotransducers [212,213]. Integrin clustering leads to the
phosphorylation of focal adhesion kinase (FAK) suggesting that FAK may mediate the
transmission of mechanical stress into biochemical signals related to EMT. EMT
preferentially occurs in response to TGF, a major inducer of EMT, at locations within
tissues where mechanical stress is concentrated [213]. For example, regions of high
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mechanical stress correlate with patterned expression of EMT markers during branching
morphogenesis [214]. Increasing the rigidity of 3D substrates induced the expression of
EMT transcription factor Snail. All of the cell lines cultured on the 3P scaffolds
underwent EMT induction. We have not explored the effects of these forces on the
induction of EMT on the 3P scaffold; however, these observations underscore the need
to examine tumorigenesis as a consequence of changes at both the cellular and
physical level of the ECM. Our novel 3P scaffold can be used to provide a 3D platform
to study the metastatic cascade as well as other aspects of tumorigenesis that are
exclusively observed in a 3D environment. Tumor-stroma interactions affect cancer
growth, metastasis and the acquisition of drug resistance. To determine if the 3P
scaffold was an appropriate in vitro model for anticancer drug screening we cultured
tumor biopsy specimens on the scaffold. 3P scaffolds supported the growth of both
tumor and stromal cells from the biopsy and this in vitro platform therefore mimic in vivo
tumor growth. Moreover, tumoroids derived from the biopsies were more resistant to
MEK and PI3K inhibitors than the tumoroids from cancer cell lines. Thus, while
tumoroids from a cell line exhibit a distinct drug sensitivity profile, they do not accurately
reflect the in vivo condition. Our biopsy results suggest that co-cultures of tumor cells
with stromal cells will produce tumoroids that better reflect the in vivo context. These
tumor/stroma effects on chemosensitivity underscore the importance of using a 3D
platform such as the 3P scaffold for growth of actual patient tumor biopsies to test the
efficacy of anticancer drugs.
In conclusion,our scaffold-based platform provides an elegant approach for developing
customized anticancer treatments. Tumor biopsies can be cultured on a 3P scaffold,
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differentiated into tumoroids and screened with an array of anticancer drugs to
determine the most effective drug combinations for a particular cancer patient within a
week. Rapid advances in genetics, genomics and related technologies are promising a
new era of personalized cancer therapy based on molecular characterization of a
patient's tumor and its microenvironment with the intent to improve outcomes and
decrease toxicity [223]. However, these molecular predictors of tumor response are far
from perfect. The heterogeneity of tumors, the lack of effective drugs against most
genomic aberrations and the technical limitations of molecular tests hamper the current
approaches for predicting the response to anticancer drugs. Our novel 3P scaffold may
provide the solution for overcoming these hurdles to rapid drug screening and
customized cancer therapy [224].
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Chapter Six
Future Work

We have developed a novel 3D scaffold with potential for HTS and personalized
medicine applications. The scaffold could be used to screen and identify novel small
molecules that target metastatic diseases and their respective stromal cells as well as
identify new uses for existing antitumor agents. The inhibitor studies indicate the
significance of signal transduction pathways in tumoroid formation on the scaffold and
further work is needed to identify the genetic pathways involved as well as those that
contribute to drug resistance. The physicochemical mechanisms responsible for
tumoroid formation on the scaffold need further elucidation. Future investigations are
needed to understand how mechanical signals such as topography, are transduced into
cancer cells and translated into signal transduction pathways that drives tumoroid
formation and EMT induction on the 3P scaffold. These investigations may include the
effects of mechanical forces such as tensile strength, strain and elasticity of the scaffold
as it has been shown that these properties of the ECM affect cancer dissemination and
impart resistance to chemotherapeutic drugs. Challenges exist to satisfying the criteria
for HTS mainly automation of the electrospinning technique, scalability to satisfy
multiple formatting requirements, low cost and wide applicability. Developing the
automated system for scaffold production would increase production over the present
system, would allow for adaptation to larger multiplate formats and would significantly
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reduce time and the cost of production. Wide applicability requires that a larger library of
cancer cell lines be tested to determine the potential for tumoroid formation including
coculture with stromal cells.
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